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8   CHAPTER 1 - General introduction
General introduction
 
Radiotherapy has a pivotal role in the treatment of head and neck cancer patients [1]. 
Currently, tumour control and survival have been improved by the combination of radio-
therapy with chemotherapy or biological agents (i.e. cetuximab) [2, 3]. The meta-analysis 
of Pignon et al. [2] showed that the overall survival improved with 6.5% after 5 years when 
radiotherapy was combined with concomitant chemotherapy. In addition, the addition of 
cetuximab to radiotherapy resulted in significantly higher rates of locoregional control and 
overall survival when combined with radiotherapy as compared to that observed after 
radiotherapy alone [3, 4].
The last decades, the incidence of patients with oropharyngeal cancer related to the human 
papillomavirus (HPV) is markedly rising [5–7]. This is relevant as patients with HPV-positive 
tumours that received radiotherapy either or not combined with concurrent chemotherapy 
showed significantly better prognosis than patients with HPV-negative tumours [8, 9]. 
The result of this improved survival is that the prevalence of head and neck cancer survivors 
at risk for radiation-induced side effects is increasing. In general, radiation-induced side 
effects are distinguished in early and late effects [10]. Early or acute effects emerge 
during or immediately after the end of therapy, while late side effects develop after latency 
periods of at least 90 days to years. In contrast to early effects, the majority of late side 
effects of radio therapy are considered to be irreversible [10]. Xerostomia is one of the most 
severe and frequently reported late side effects that has a major influence on quality of life 
[11–13]. Furthermore, swallowing problems are frequently reported and have a notorious 
effect on quality of life [13].
Intensity modulated radiotherapy (IMRT) can be applied to conform doses sufficient to 
eliminate all viable cancer cells within the target region, while sparing organs at risk 
(OARs) as much as possible. It has been shown that the introduction of IMRT resulted in a 
sig ni ficant improvement of the recovery of saliva secretion and a reduction of xerostomia 
[14–16]. Still, with currently used concomitant chemo-radiation regimens, the limits of 
accep table toxicity have been reached with more than half of the patients treated with  
IMRT suffering from moderate to severe xerostomia 6 months after treatment [17]. 
Normal tissue complication probability (NTCP) models [18] are used to estimate the 
probability that patients develop radiation induced side effects. Many types of models that 
relate dose-volume characteristics to outcome have been proposed in the literature. The 
Lyman-Kutcher-Burman model was one of the earliest proposed [19, 20], followed by other 
models that attempt to explicitly model tissue architecture [21–23]. All of these models use 
information only about fractionation and the dose distribution in a single organ at risk. Since 
the probability of a complication may be affected also by multiple clinical prognostic factors, 
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El Naqa et al. were one of the first who proposed other approaches using multivariable 
logistic regression analysis [24]. Input parameters to these models are usually clinical and 
dosimetric factors. 
The dose to the parotid glands is the most important factor associated to xerostomia-related 
endpoints [17, 25, 26]. For swallowing problems, the dose to several swallowing structures 
are of major importance [27].
NTCP and tumour control probability (TCP) models can be applied to optimize the treatment 
plan, i.e. minimizing the risk for side effects with equal or higher TCP [28]. Furthermore, 
NTCP and TCP models can be applied to compare different treatment plans and to select 
patients for more advanced treatments such as adaptive radiotherapy (ART) and proton 
therapy [29].
A number of uncertainties in the preparation and delivery of radiotherapy exists, which 
should be minimized to accurately develop and reliably apply NTCP models [30]. Reducing 
the uncertainties could also lead to smaller treatment margins or smaller robustness 
parameters in treatment planning, leading to a higher plan quality (i.e. good target coverage 
with lower dose to the OARs). Dose distributions of IMRT plans are much more sensitive 
to these uncertainties than 3D-CRT plans, because of the steeper dose gradients in IMRT 
treatment plans. The most important uncertainties include setup variation, delineation 
variability, and anatomical variation (variation in shape/position of targets and organs 
within the patient) [31]. Setup variation in the head and neck area is in the order of 2 mm 
standard deviation (SD) [32]. Setup variation can be accounted for in position verification 
protocols, and will be outside the scope of this thesis. 
Variability in delineation
Variability in the delineation of targets is found to be the largest source of uncertainty (i.e. 
the weakest link) in head and neck radiotherapy, with standard deviations of 3.4-7.7 mm 
for CT-based GTV delineation in nasopharynx cancer [33]. Variability in delineation of target 
volumes and OARs could result in sub-optimal treatment plans with systematic dose errors 
for all treatment fractions [33, 34]. This may result in inconsistent patient treatments and 
inconsistent reported dose parameters, with a potential under- or overestimation of the 
patients’ TCP and NTCP [35]. 
Variability in delineation is caused by a number of aspects; limited imaging resolution 
[36], intra-observer variation (‘observer noise’ and the precision of the delineation tool) 
[37] and interpretation differences, caused by different guidelines and/or differences with 
regard to the level of education and frequency of training [38, 39]. More and better quality 
imaging has become available and CT-slice distance is generally reduced to 2 mm. Also, 
more and more dedicated software for contouring has become available and education 
and training sessions are being organised on a regular basis (European training sessions 
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and delineation meetings at individual departments). For target volumes, international 
consensus guidelines have been defined to minimize variability in delineation and optimize 
consistent radiotherapy practice [40, 41]. For OARs however, such guidelines are lacking. 
The introduction of consensus guidelines are expected to result in reduced interobserver 
variability [42].
Anatomical variation during the treatment
The pre-treatment CT on which IMRT plans are based, is only a snapshot of the patient’s 
anatomy. Barker et al. [43] were one of the first who reported on variability in shape 
and position of head and neck targets and OARs within the patient during the course of 
radiotherapy. The median volume loss on the last day of treatment was 69.5% for the GTV 
and 28.1% for the parotid glands. The parotid glands also shifted medially over time, the 
median medial shift of the centre of mass was 3.1 mm at the end of treatment [43]. Robar 
et al. [44] reported shortly thereafter on the consequences of the anatomic changes for 
the dose distribution. On average, dosimetric changes were moderate, but for a couple of 
patients outliers were seen (standard deviation and range of dosimetric changes of the 
parotid gland were 6 and 15% respectively).
Since 2010, the amount of studies reporting on anatomical and dosimetric changes has 
increased dramatically [45–65]. Variation in anatomy causes more dose deviations in OARs 
than in target volumes [66–69]. Not all of the studies reported to what extent anatomical 
changes translate into dosimetric changes, and for which group of patients this would 
actually be of clinical relevance. In the study of Chen et al. [67], mean dosimetric changes to 
the parotid gland mean dose of 10.4 Gy were found, whereas Castadot et al. only reported 
changes of 0.8 Gy [70]. This pleads for a careful introduction of adaptive radiotherapy 
since only a selected set of patients would benefit from an extremely labour and resource 
intensive procedure. Theoretically, adaptive radiotherapy could be fully auto mated, as Yan 
et al. introduced in 2005 [71]. The authors predicted that adaptive radio therapy will become 
a new treatment standard that will eventually replace the pre designed treatment plan in 
routine clinical practice. However, to date and more than 10 years later, online adaptive 
radiotherapy still remains a future perspective due to its labour and resource intensive 
nature. Furthermore as yet, no commercial conclusive solution is available for a save and 
controlled workflow. Therefore, ‘flags’ to select patients for which ana tomic changes result in 
relevant dose deviations need to be established, to  be able to select specific patients for an 
adaptive radiotherapy schedule. 
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Outline of the thesis
 
Minimizing the uncertainties in delineation and position and shape of the OARs is expected 
to result in improved and more general applicable NTCP models. It is of major importance 
to accomplish generally applicable NTCP models, since these models are essential tools in 
selecting patients for advanced treatments [29], and in optimizing the treatment plans for 
every individual patient to guarantee optimal quality of life. 
In this thesis, we will focus  on variability in delineation and how to minimize its effect on 
dose in chapters 2, 3 and 4. Chapter 5 and 6 will focus on anatomical variability during the 
course of treatment and its effect on the dose distribution.
Chapter 2 reports on the differences between several OAR delineation guidelines, and its 
effect for dose-volume parameters and corresponding predictions of NTCP models. 
Chapter 3 subsequently shows the variation in delineation of OARs within a guideline, 
with detailed analysis on sub-regions of the OARs. Causes of interobserver variability and 
differences between the different sub-regions are discussed.
With the knowledge of Chapter 2 and 3, in Chapter 4 international consensus guidelines for 
the delineation of the most important OARs in the head and neck area are presented. 
Chapter 5 reports on a systematic review on anatomic and dosimetric changes of head and 
neck OARs during the course of radiotherapy. Also, factors related to these changes are 
studied which could potentially be used to select patients at risk for dosimetric changes of 
OARs in an adaptive radiotherapy protocol.
Finally, the potential pre-treatment selection parameters identified in Chapter 5 are tested 
in Chapter 6 in a cohort of 113 patients. A method to select patients at risk for dosimetric 
changes of the parotid glands is established, and validated in another, independent patient 
cohort.
The findings of this thesis are summarized and discussed in Chapter 7.
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ariability in the  
delineation of head and 
neck organs at risk: 
Variation between guidelines 
and impact on dose and NTCP
CHAPTER 2




To test the hypothesis that delineation of swallowing organs at risk (SWOARs) based on 
different guidelines results in differences in dose-volume parameters and subsequent 
normal tissue complication probability (NTCP) values for dysphagia-related endpoints.
Materials and Methods
Nine different SWOARs were delineated according to five different delineation guidelines in 
29 patients. Reference delineation was performed according to the guidelines and NTCP-
models of Christianen et al. Concordance Index (CI), dosimetric consequences, as well as 
differences in the subsequent NTCPs were calculated.
Results
The median CI of the different delineation guidelines with the reference guidelines was  
0.54 for the pharyngeal constrictor muscles, 0.56 for the laryngeal structures and 0.07 for 
the cricopharyngeal muscle and esophageal inlet muscle. The average difference in mean 
dose to the SWOARs between the guidelines with the largest difference (maxΔD) was 3.5  
± 3.2 Gy. A mean ΔNTCP of 2.3 ± 2.7% was found. For two patients, ΔNTCP exceeded 10%. 
Conclusions
The majority of the patients showed little differences in NTCPs between the different 
delineation guidelines. However, large NTCP differences >10% were found in 7% of the 
patients. For correct use of NTCP models in individual patients, uniform delineation 






In head and neck radiotherapy, reducing the dose to healthy tissues is important, since 
radiation damage to organs at risk (OARs) may result in severe complications during 
and after completion of treatment. Some radiation-induced complications, in particular 
swallowing dysfunction, have a significant impact on health-related quality of life as reported 
by patients [1, 2]. 
Several guidelines for OAR delineation have been published [3–11]. However, the definition, 
selection and delineation of OARs vary widely among the different publications and authors. 
This may lead to unjustified comparisons between institutes that apply different guidelines, 
jeopardizing the translation of results published into routine clinical practice. 
Studies on the development of normal tissue complication probability (NTCP) models have 
identified numerous predictive factors for the development of radiation-induced dysphagia, 
such as the radiation dose to anatomical structures involved in swallowing dysfunction  
(e.g. the superior pharyngeal constrictor muscle)[12]. NTCP models can be used to estimate 
the risk of a given complication. Moreover, the most important dose volume parameters 
included in these NTCP-models can be used for treatment plan optimization, and thus to 
compare different radiation treatment plans in order to select the most optimal treatment. 
Radiation doses to specific swallowing organs at risk (SWOARs) are main parameters for 
the calculation of NTCPs of dysphagia. NTCPs directly result from specific dose parameters 
of the SWOARs. However, if the delineation of SWOARs markedly differs from the guidelines 
used for NTCP-model development, the translation of the results of such models into routine 
clinical practice may be incorrect. 
Recently, Christianen et al.[12] published delineation guidelines for SWOARs in head 
and neck radiotherapy that differ at some points from the definitions of SWOARs and 
sub sequent delineation guidelines used by other investigators [4–11]. So far, the magnitude 
of these differences is still unclear, and the possible clinical relevance regarding differences 
in corres ponding NTCPs remains to be determined.
Therefore, the main objective of the present study was to test the hypothesis that SWOAR 
delineations based on different delineation guidelines lead to differences in dose-volume 
parameters and subsequent NTCPs for dysphagia.
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Materials and Methods
 
Delineation guidelines and patients
For the purpose of the present study, the guidelines as proposed by Christianen et al. 
were used as a reference [3]. We decided to use this publication as a reference as it was 
the only one dedicated to the description of SWOARs delineation guidelines and because 
these guidelines were actually used in a subsequent publication that reported on the 
development of multivariate NTCP-models for different endpoints related to dysphagia 
[12]. This publication also included an overview of eight other guidelines for delineation 
of SWOARs that were published between 2000 and 2010 [4–11]. The following SWOARs 
were included in this overview: the pharyngeal constrictor muscles (PCMs), cricopharyngeal 
muscle and ‘esophageal inlet muscle’ (EIM) (which was previously described as ‘1 cm of the 
muscular compartment of the esophageal inlet’ (10) and ‘upper esophageal sphincter’ (9)) 
and the glottic and supraglottic larynx. For the purpose of the current study, we extracted 
the definitions from the original papers and defined different delineation groups (DGs) by 
clustering the structures into groups with corresponding definitions (Table 1). These groups 
with corresponding definitions will be referred to as ‘DG1’, ‘DG2’, etc..
The information in Table 1 was confined to the definitions of the cranial and caudal borders 
of the SWOARs, since the definitions of these borders showed the largest variation.  
A detailed description of all remaining borders can be found elsewhere [3]. 
SWOARs were delineated in Pinnacle3 v9.0 (Philips, Madison) in 29 sample patients from 
our clinic according to the different guidelines of the DGs, resulting in a total number of 899 
contoured SWOARs. Contouring was performed by one observer (EG) and checked by two 
others (MK and RS). The contours according to all DGs of the SWOARs which are input to the 
studied NTCP-models [12] are shown in Fig. 1. 
Patients were randomly selected from our previous cohort [12]. The set comprised 6  laryn-
geal, 4 hypopharyngeal, 1 oral cavity, 15 oropharyngeal and 3 nasopharyngeal patients 
[13]. Planning computed tomography (CT)-scans were acquired in supine position with a  







Overview of delineation guidelines for swallowing organs at risk (SWOARs) and the clustering into 
delineation groups (DGs) with corresponding definitions. The number of different  definitions and 
therefore the number of DGs varies per structure. SWOARs used as input parameters of NTCP 
models [12] are marked by *.
SWOAR Delineation groups (DGs) of corresponding definitions
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SWOAR Delineation groups (DGs) of corresponding definitions
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Geometric differences between the DGs were expressed as the Concordance Index 
(CI) of the different DGs with the reference DG (DG1). The CI provides information on 
volume as well as on positional differences [14]. The CI is the ratio of the intersection 
(Volume1∩Volume2) and union (Volume1UVolume2) volume of two delineated volumes. A 
CI of 1.00 indicates perfect overlap (identical structures), whereas a CI of 0.00 indicates no 
overlap at all.
Dosimetric comparison
Standard clinically acceptable photon intensity modulated radiation therapy (IMRT) 
treatment plans were available for all patients. Plans were reviewed and/or replanned by a 
single experienced dosimetrist (HPL) for the purpose of plan consistency. When replanning 
(plan adjustment) was performed, this was done to make sure that: (1) Coverage of the 
planning target volumes (PTV) was adequate (exactly 98% of the PTV should receive 95% of 
the prescribed dose); (2) The mean dose in the parotid glands was as low as possible; (3) 
The dose outside the PTV was reduced as much as possible (optimized dose conformity). 
No efforts were taken to specifically reduce the dose to the SWOARs [13]. Thus, the IMRT 
treatment plans were not influenced by the SWOARs delineations. 
We studied the differences in mean doses in the SWOARs between the different DGs. For 
each patient the two DGs that resulted in the largest difference in mean dose (maxΔD) 
for a particular SWOAR were selected. MaxΔD was averaged over all patients to obtain an 
average maxΔD per SWOAR. Estimates of the variability in this study are always reported as 
±1 standard deviation (SD).
NTCP comparison
NTCPs were estimated for DG1 and DG2, in order to translate the differences in dose to 
differences in NTCPs. This will demonstrate the deviation from the model (ΔNTCP) in the 
situation of a clinical practice in which the contouring guidelines of DG2 are achieved, while 
the NTCP model belonging to DG1 is adopted. The analysis was confined to DG2 since it 
contained the most complete set of SWOARs’ description in relation to DG1. Differences in 
the NTCPs between DG1 and DG2 (ΔNTCP) were calculated for each patient, based on four 
equations published by Christianen et al. [12]. The NTCP-models contained the endpoints: 
• swallowing dysfunction grade 2-4 at 6 months after completion of radiotherapy,  
 according to the RTOG Late Radiation Morbidity Scoring Criteria (1)
• patient-rated moderate-to-severe problems with swallowing solid (2), soft (3) and  
 liquid (4) food 
Table 2 lists the various parameters in the four different NTCP models. Radiation technique 
was IMRT for all patients in this study. 
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TABLE 2 
Overview of S-values for physician- and patient-rated swallowing dysfunction according to 
institutional prediction models [12] .
Swallowing dysfunction s-value
RTOG grade 2-4 s = -6.09 + (mean dose superior PCM×0.057) +  
(mean dose supraglottic larynx×0.037)
Liquid food s = -5.98 + mean dose supraglottic larynx×0.074+   
(radiation technique×-1.209)
Solid food s = -6.89 + mean dose superior PCM×0.049+  (mean dose supraglottic 
larynx×0.048) + (age×0.795) 
Soft food s= -5.83 + mean dose middle PCM×0.061+age×1.203+ tumour site× 
1.122  +(radiation technique×-0.912)  
Choking s=-7.07 + V60 EIM×0.020+   
(mean dose supraglottic larynx×0.066)
NTCP calculations were based on a standard model of El Naqa [22]. Its mathematical 
definition was described in (1). The s-value differed for each model and its value was a 
summation of the dose and weights for the OARs for that specific model. The resulting NTCP 
gave the chance on complications for the OARS as a value between 0 and 1. 
 
NTCP =        1       (1)                 (1+e)-s
In which
S = β0 + ∑
n
i = 1βi ∙ Xi 
The S-values of the different models are given in Table 2. The age-factor was 0 for patients 
of age 18-65 and 1 for patients of an age above 65. In terms of radiation technique a 0 was 
for 3D-CRT and a 1 for IMRT. The tumour site value was 1 when it was primary located at the 






A statistically significant difference in SWOAR volume was observed between the different 
DGs (p < 0.05, two-way ANOVA, Table 3). Fig. 2 illustrates the CI of the different DGs 
reference to DG1 for each SWOAR. 
The average median CI value was 0.54 for the PCMs, 0.56 for the laryngeal structures and 
0.07 for the cricopharyngeal muscle and EIM. For the cricopharyngeal muscle no overlap 
at all with DG1 was seen (CI = 0). CIs of a certain DG reference to DG1 varied between 
patients due to different anatomy and/or different flexion of the neck.
FIGURE 1 
Swallowing organs at risk (SWOARs) according to the different delineation groups 
(DGs) in one patient. Sagittal view. PCM = pharyngeal constrictor muscle.
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Boxplot of the Concordance Index (CI) of the DGs in relation to  DG1 in all 29 patients. No data 
for the cricopharyngeal muscle as a separate structure is presented since the CI with DG1 was 
0 for all patients. sup= superior, med= middle, inf= inferior and total= total structure.
 
Boxplot parameters: The bottom and top of the box are the 25th and 75th percentile (the 
lower and upper quartiles, respectively) of the data. The error bars represent the minimum and 
maximum values of the data.
FIGURE 2
Dosimetric comparison 
Differences in SWOAR mean dose between the DGs showed moderate to large variations 
(Fig. 5). Largest maxΔD was found for patient 11, for which the difference in mean dose to 
the PCM superior between DG1 and DG3 was 19.1 Gy. The average maxΔD of all SWOARs 
was 3.5 ± 3.2 Gy with the largest differences observed for the total PCM (6.0 ± 3.4 Gy), 
while differences for the glottic larynx (0.8 ± 0.9 Gy) remained limited.
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Difference in normal tissue complication probabilities (ΔNTCP) between delineation group 
(DG) 1 and 2 for different complications [12]. ΔNTCP>0 means underestimation and 
ΔNTCP<0 means overestimation of the NTCP using DG2 in relation to DG1. Tumour location 
is indicated by grey/ white filling of the bars.
FIGURE 3 
NTCP comparison
Fig. 3 depicts ΔNTCP between DG1 and DG2 for the four NTCP-models studied. The mean 
absolute ΔNTCP over all patients and complications was 2.3 ± 2.7%. Differences were 
related to patient’s anatomy, posture and primary tumour site. Patients with tumours 
located in the oropharynx or nasopharynx showed higher NTCPs for the DG1-based SWOARs, 
while for patients with tumours located in the larynx and hypopharynx, the DG2-based 
SWOARs showed the highest NTCPs (grey vs. white bars in Fig. 3, respectively). This is mainly 
due to the larger overlap between the planning target volume (PTV) and the DG1-based 
SWOARs with respect to the DG2-based SWOARs for oropharynx/nasopharynx patients, 
and vice versa for larynx/hypopharynx patients.  For two patients, the absolute ΔNTCP for 
at least one of the endpoints was larger than 10%. For patient 12 (primary tumour location 
in oropharynx), the mean dose to the supraglottic larynx according to DG1 was 70.5 Gy and 
for DG2 57.7 Gy (Fig. 4). The resulting ΔNTCP for RTOG grade 2-4 swallowing dysfunction 
was 11.6% (61.6% vs. 50.0%). For problems with swallowing solid food, ΔNTCP was 14.5% 
(47.3% vs. 32.8%). For the other patient (primary tumour located in oropharynx), ΔNTCP was 
10.9% (35.0% vs. 24.1%) for the endpoint swallowing soft food (Fig. 3).
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Discussion
 
This is the first study on the effect of variation in delineation guidelines on dose and 
subsequent NTCPs. We showed that dose parameters and corresponding NTCPs may vary 
widely depending on the definitions of the SWOARs. For the set of head and neck SWOARs 
included in the present study, the average maximal dose difference (maxΔD) was 3.5 ± 3.2 
Gy. The translation of the dose variation to variation in NTCP for DG1 vs. DG2 resulted in a 
mean absolute ΔNTCP of 2.3 ± 2.7% (average over all patients and all four NTCP models 
studied). On average this seems a moderate difference, but it should be stressed that 
in individual cases ΔNTCP was much larger (>10%), which may lead to incorrect NTCP-
predictions and possibly unjustified clinical decisions.
The magnitude of deviations from the reference volumes, dose, and subsequent NTCPs 
depended on patient’s anatomy and posture, as well as on primary tumour site. The impact 
of the variation in patient anatomy was illustrated well in the box plots of the CI of Fig. 2 
(large interquartile distances). This spread of CI values may be explained by the fact that 
for some patient anatomies and postures, the demarcations (e.g. certain bone and muscle 
structures) of different DGs may be more separated than for other cases. For example, 
patients with primary tumour sites located in the oropharynx or nasopharynx showed 
relatively large differences in NTCPs due to dose variation in the supraglottic larynx, while 
these differences were much smaller for laryngeal and hypopharyngeal cancers. According 
to DG1, the supraglottic larynx extends to the tip of the epiglottis, while according to DG2 
Dose distribution (sagittal view) and dose-volume histogram of the supraglottic larynx for 




the cranial border ends at the upper extension of the piriform sinus and aryepiglottic fold. 
Therefore, the overlap of the supraglottic larynx with the PTV in oropharyngeal cancer will 
generally be larger when using DG1 compared to DG2, resulting in higher dose values for 
DG1 compared to DG2 (Fig. 4). Therefore, the NTCP for patient-rated moderate-to-severe 
problems with solid, soft and liquid food (for which the model includes the mean dose to 
the supraglottic larynx) was smaller for DG2 compared to DG1 (Fig. 3). For patient-rated 
moderate-to-severe problems with swallowing soft food, applying DG2 for contouring 
the middle PCM also resulted in underestimation of the NTCPs for patients with primary 
tumours located in the oropharynx in relation to DG1 due to less overlap of the PTV with the 
SWOAR using DG2. 
The large differences in NTCPs in some individual patients emphasize the importance 
of uniform delineation guidelines. We propose to develop general consensus guidelines, 
which should be simple and unambiguously described. Probably, current delineation 
guidelines differ most because of different interpretation of anatomy, and different choices 
for (derived) structure borders. However, before we will be able to define a pragmatic 
set of simple delineation guidelines, we believe it is important to study dose-response 
relationships for swallowing problems more extensively and to understand the physiology 
of side effects, to be able to include the best predictive parameters in NTCP models. The 
(superior) pharyngeal constrictor muscles [15, 16] and the supraglottic larynx [15] were, 
similar to our own research [12], recently associated with late radiation induced dysphagia. 
Besides, De Ruyck et al. found that the rs3213245 (XRCC1) polymorphism was associated 
with radiation induced dysphagia [16]. Integrating biological and genetic (polymorphisms) 
information is promising to improve and individualize NTCP models.
Consensus meetings, multi-modality imaging, and the use of auto delineation tools could 
facilitate the introduction of uniform delineation guidelines [17, 18]. The findings of this 
study may also have implications for the design of clinical trials, especially when radiation-
induced dysphagia is a primary or secondary endpoint. In these cases (automated) review 
of delineations is recommended. Although there still may be differences resulting from 
interobserver variability, the concordance of head and neck OAR delineations within a 
guideline appears to be better than those between guidelines (results of this study) [19].
Feng and colleagues [20] reported on the effect of contouring variability and the resulting 
impact on IMRT treatment plan optimization in oropharyngeal cancer. A contouring 
variability up to 1.4 cm led to a 0.9 Gy mean difference between optimizations. We can, 
however, not compare the results of that study with our results, since these investigators 
studied variation in delineation of repeated delineations by a group of experts, while 
the current study focussed on inter-guideline variation. Moreover, these investigators 
studied dose differences between optimizations (thus between different treatment plans) 
on different contours, while we studied the effect of using different guidelines for NTCP 
estimation within one treatment plan.
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From a scientific point of view, it is important to externally validate NTCP-models developed 
in specific institutions, before they can be used in routine clinical practice. The results 
of the present study clearly illustrate that this external validation may be hampered by 
inconsistencies in delineation guidelines. This is particularly true for SWOARs with large 
dose variation and for NTCP-models for which the results are more sensitive to differences 
in contouring. Previous work has shown that the way we measure dysphagia (physician-
rated, patient-reported, or objective measurements) is also of main importance for 
consistent NTCP modelling [21]. Therefore, clear definitions of organs at risk and endpoints 
are required to improve the external validity of NTCP-models.
The present study showed the consequences of not applying the matching input data to 
NTCP-models. In theory, all delineation guidelines would fit their own NTCP models. In 
practice however, multiple model versions should be constructed and validated, and this 
would also rule out pooling of dose-volume and follow-up data into large data sets to build 
a proper NTCP-model. We would therefore strongly advocate the use of uniform guidelines 
for NTCP-modelling studies as well as for studies on external validation and routine clinical 
practice. 
In the current study, mean dose and corresponding NTCP differences between DGs were 
compared using IMRT plans that were not optimized based on the dose to the SWOARs, 
but particularly on the dose to the parotid glands.  Therefore, the question arises what 
happens with the dose differences if the IMRT plans would be optimized for the different 
DGs. We expect the dose differences between the DGs to be similar or even larger when 
optimization on SWOARs would be performed, since dose gradients would be located closer 
to the SWOARs, resulting in larger dose differences between the different DGs. SWOAR 
optimization for different DGs was performed in two of our study patients, and results 
confirmed our presumption (see Appendix for a case example).
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Mean dose to the swallowing organs at risk according to the different delineation 
groups (DGs), sorted on largest difference (left-right). PCM= pharyngeal constrictor 
muscle, CP= cricopharyngeal muscle, EIM = esophageal inlet muscle.
FIGURE 5
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SWOAR Volume (cc)*
DG1 DG2 DG3 DG4 DG5 p-value**
Total PCM 20.8 (4.9) 29.9 (6.9) 22.4 (6.2) 26.7 (7.2) 9.8 (3.6) 0.000
Superior PCM 7.6 (1.8) 12.5 (3.6) 4.5 (1.4) 9.9 (3.8) - 0.000
Middle PCM 4.3 (2.2) 2.6 (0.9) 5.3 (2.8) - 0.000 0.000
Inferior PCM 4.8 (1.3) 10.1 (2.8) - - - 0.000
Larynx 21.1 (6.2) 9.0 (4.0) 18.7 (5.5) 16.2 (5.9) - 0.000
Supraglottic 
Larynx
10.9 (3.5) 9.2 (4.1) - - - 0.041
Glottic Larynx 7.4 (2.9) 5.1 (1.8) - - - 0.000
Cricopharyngeus 3.7 (1.4) 1.8 (0.6) 0.8 (0.3) - - 0.000
Cricopharyngeus 
& EIM
5.9 (1.9) 0.6 (0.4) 3.0 (0.9) - - 0.000
* Variables are denoted as mean (standard deviation).  
** Group differences were tested with Friedman’s ANOVA.
TABLE 3 
 
Volume of swallowing organs at risk (SWOARs) for the different delineation groups (DGs).  
PCM = pharyngeal constrictor muscles. EIM = esophageal inlet muscle.
Conclusion
 
The majority of the patients showed little differences in NTCPs for different delineation 
guidelines. However, large NTCP differences >10% were found in 7% of the patients. For 






Standard versus Swallowing sparing IMRT plans
This section shows that in standard as well as in swallowing sparing IMRT (when plans are 
optimized by reducing the dose to the SWOARs as well), deviations in NTCP-values remain if 
delineations of DG2 are used instead of DG1 (NTCP-model based on DG1).
In this example, we calculated the NTCP-value for grade II-IV dysphagia based on the mean 
dose to the superior PCM and supraglottic area for two different delineations (DG1 and 
DG2) (Figure 2). In addition, the treatment plan was optimized by reducing the dose to the 
SWOARs, resulting in plan DG1-optimized and plan DG2-optimized. The NTCP-values for the 
different plans were then calculated again (Table S1).
Figure S2 shows dose volume histograms of the PCM superior for the standard and the 
DG2-optimized IMRT plan. For both the standard and optimized plan (solid and dashed 
lines, respectively), the dose to the PCM superior based on the DG2 delineation (in red) 
deviated from the dose according to the DG1 delineation (in green). 
For the incorrect situation, the NTCP is calculated based on the dose according to the DG2 
delineation (red lines in Figure S2). The corresponding NTCP-value for the DG2-optimized 
IMRT plan was 9.3%, while the correct NTCP-value for this dose distribution, based on the 
DG1 delineation (dashed green dose-volume line in Figure S2), should be 6.1% (Table S1). 
This absolute difference of 3.3% in NTCP translates into a relative NTCP overestimation of 
54%. Although in this case the absolute difference is relatively small, this example proves 
that optimized IMRT based on SWOARs do not automatically reduces the problem of under- 
or overestimation of NTCP-values.
So for both standard and swallowing sparing IMRT plans, similar errors are made if incorrect 
NTCP model parameters are used.
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FIGURE S1
Delineations of 
the PCM superior 
ad supraglottic 
larynx (green= 
DG1, red= DG2) 
and PTV70 
(purple).
Dose volume histograms (DVHs) of the PCM superior for two different IMRT 
plans (solid: standard IMRT, dashed: DG2-optimized IMRT) and the two different 
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Consistent delineation of patient anatomy becomes increasingly important with the growing 
use of highly conformal and adaptive radiotherapy techniques. This study investigates the 
magnitude and 3D localization of interobserver variability of organs at risk (OARs) in the 
head and neck area with application of delineation guidelines, to establish measures to 
reduce current redundant variability in delineation practice.
Methods
Interobserver variability among five experienced radiation oncologists was studied in a set of 
12 head and neck patient CT scans for the spinal cord, parotid and submandibular glands, 
thyroid cartilage, and glottic larynx. For all OARs, three endpoints were calculated: the 
Intraclass Correlation Coefficient (ICC), the Concordance Index (CI) and a 3D measure  
of variation (3D SD).
Results
All endpoints showed largest interobserver variability for the glottic larynx (ICC = 0.27, mean 
CI = 0.37 and 3D SD = 3.9 mm). Better agreement in delineations was observed for the 
other OARs (range, ICC = 0.32–0.83, mean CI = 0.64–0.71 and 3D SD = 0.9–2.6 mm). 
Cranial, caudal, and medial regions of the OARs showed largest variations. All endpoints 
provided support for improvement of delineation practice.
Conclusions
Variation in delineation is traced to several regional causes. Measures to reduce this 
variation can be: (1) guideline development, (2) joint delineation review sessions and (3) 







Radiotherapy (RT) plays an important role in the treatment of head and neck cancer 
patients. Many new radiation delivery techniques such as intensity-modulated RT (IMRT) 
have been developed to allow improved dose conformation with steeper dose gradients 
compared with conventional three-dimensional conformal RT. Variation in contouring is an 
important obstacle in the development of high geometric accuracy in the clinical application 
of these new techniques. Reproducibility in delineation of tumour and normal structures is 
of importance for optimal patient treatment [1]. As new radiation delivery techniques are 
increasingly controlled by OAR constraints for normal tissue sparing [2], variations in OAR 
delineation may unintentionally influence the treatment plan including the dose to these 
OARs [3]. In a number of publications (e.g. Bortfeld and Jeraj [4]), uncertainties in the 
contouring of organs is also mentioned as one of the potential causes for uncertainties in 
historical dose and volume data and therefore reduced performance of predictive models. 
Deasy et al. [5] furthermore mentioned that differences in segmentation procedure could 
be one of the reasons explaining variations between existing models.
Target volume delineation variability in the head and neck area has been investigated in 
several studies (e.g. Rasch et al. [6]), indicating the need to minimize observer variation 
for adequate irradiation. However, interobserver variability of OARs in the head and neck 
area has not been frequently studied. Nelms et al. [3] found significant organ-specific 
interclinician variation for head and neck OARs. These variations resulted in large 
differences in dose distribution parameters, especially in high dose gradient regions. The 
authors stated that the major variations were in each observer’s interpretation of the OARs 
actual size and shape, suggesting the need for basic training (with unambiguous guidelines) 
on identifying OARs. Our department uses well-defined delineation guidelines to promote 
the consistency and accuracy of delineation such as the recently described guidelines for 
the delineation of OARs related to salivary dysfunction and anatomical structures involved in 
swallowing [7,8]. Interobserver variation in the contouring of OARs is therefore intended to 
be minimal, but still there will be regions in the OARs which are difficult to interpret for the 
observer. Accurate determination of variation in OAR delineation expressed in volumetric, 
positional and local 3D measures is therefore needed to establish current accuracy 
status, to bring actual weaknesses to light and to establish measures to reduce current 
redundant variability in delineation practice. More consistency in the delineation of OARs 
may contribute to more consistent dose volume data, and thus less uncertainty in the usage 
of dose volume characteristics. With the unambiguous and consistent contouring of OARs 
we could furthermore generalize the application of normal tissue complication probability 
(NTCP) models. We might even be able to develop improved models, when more consistent 
dose-volume data is correlated with clinical outcome. This is particularly important for 
the rising application of particle therapy, in which the dose gradients are extremely steep. 
The obtainable level in accuracy of delineations also provides valuable information for the 
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evaluation of tools for automatic (re-)contouring. Qazi et al. [9], for instance, reported high 
accuracy for automatic segmentation within a clinically-acceptable segmentation time, but 
also mentioned the need for multi-observer studies to give more insight in the robustness, 
reliability, and stability of the automated approach. Existing variations in expert delineations 
could serve as benchmark data.
The aim of the current study was to indicate OAR regions with high interobserver variability 





The study population was composed of 6 head and neck cancer patients. These patients 
underwent a planning CT scan (CTplan) which was acquired prior to radiation, and a repeat CT 
scan (CTrep) which was acquired during the course of radiation. CTrep scans were performed 
11 to 35 days (range) after the start of radiotherapy. The CT images were made with the 
patient in supine position on a multidetector-row spiral CT scanner (Somatom Sensation 
Open, 24 slice configuration; Siemens Medical Solutions, Erlangen, Germany). The 
acquisition parameters were: gantry un-angled, spiral mode, rotation time 0.5 s, 24 detector 
rows at 1.2 mm intervals, table speed 18.7 mm/rotation, reconstruction interval 2 mm at 
Kernel B30 and 120 kVp/195 mA. The matrix size was 512 × 512, with a pixel spacing of 
0.97 × 0.97 × 2.0 mm in the x, y and z directions, respectively.
Five specialized head and neck radiation oncologists (R.S., A.N., H.B., O.C. and F.B.), 
all treating more than 50 head and neck patients per year, delineated five OARs on 
axial CT slices in all CT images. The radiation oncologist did not have clinical patient 
information additional to the CT scan. The OAR set included the spinal cord, the parotid and 
submandibular glands, the thyroid cartilage, and the glottic larynx. For one patient, the right 
parotid gland contained tumour infiltration and therefore the patient was excluded from 
analysis for this particular OAR beforehand. The total number of delineated structures was 
410.
CTplan and CTrep were delineated under slightly different circumstances, since CTplan was made 
with contrast-enhancement (iodine containing contrast medium, intravenously applied) 
while CTrep was acquired without contrast enhancement. Furthermore, the CTplan scan was 
delineated from scratch and the CTrep scan was delineated using a template obtained 
from the delineated contours of the CTplan, which were propagated to CTrep after a rigid 




The radiation oncologists were instructed to delineate the parotid and submandibular 
glands according to the delineation guidelines of van de Water et al. [7].
Following these guidelines the parotid gland was demarcated in lateral direction by a 
hypodense area corresponding to subcutaneous fat and more caudally by the platysma. 
The medial border was defined by the posterior belly of the digastric muscle, the styloid 
process and the parapharyngeal space. The cranial aspect of the parotid gland was related 
to the external auditory canal and mastoid process. Caudally, the gland protruded into 
the posterior submandibular space inferior to the mandibular angle. The anterior border 
was defined by the masseter muscle, the posterior border of the mandibular bone and 
the medial and lateral part of the pterygoid muscle. The posterior border was delimited by 
the anterior belly of the sternocleidomastoid muscle and the lateral side of the posterior 
belly of the digastric muscle. The external carotid artery, the retromandibular vein and the 
extracranial facial nerve are prescribed to be enclosed in the parotid gland.
Cranial demarcation of the submandibular gland was defined by the medial pterygoid 
muscle and the mylohyoid muscle, the caudal demarcation by fatty tissue. The anterior 
border was the lateral surface of the mylohyoid muscle and the hyoglossus muscle, and the 
posterior border the parapharyngeal space and the sternocleidomastoid muscle. Lateral 
demarcation was described by the medial surface of the medial pterygoid muscle, the 
medial surface of the mandibular bone and the platysma. The medial border was finally 
described by the lateral surface of the mylohydoid muscle, the hyoglossus muscle, the 
superior and middle pharyngeal constrictor muscle and the anterior belly of the digastric 
muscle.
The spinal cord was delineated as the actual spinal cord instead of using bony structures 
as surrogate for the spinal cord, starting at the tip of the dens and ending at the level of the 
third thoracic vertebra. The thyroid cartilage was delineated as the actual thyroid cartilage. 
The cranial border of the glottic larynx was defined as the arythenoid cartilages and the 
caudal border as the edge of the cricoid.
Statistical considerations
For all observers, mean volumes and standard errors (SEs), as well as coefficients of 
variation (CVs) per OAR were calculated. In addition, an ‘OAR ratio’ for each observer was 
determined, which was defined as the ratio of the mean OAR volume per observer divided 
by the mean volume of that OAR determined by all observers. Friedman’s test was applied 
to the CTplan data per OAR separately to investigate a possible systematic effect in the 
determination of volumes by the observers.
We used different endpoints to investigate interobserver variability. Variations in volume 
were indicated by the Intraclass Correlation Coefficient (ICC), and differences in combined 
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volume and positional variations by the Concordance Index (CI). Local variations in 
delineation were finally described by the regional 3D SD. Integration of these three 
endpoints could help us to identify the type of variation in delineation.
Intraclass correlation coefficient
Analysis of variance (ANOVA) was conducted for estimation of the ICC per OAR. The ICC 
quantifies how well the observers defined the same size of volumes, without considering 
the position of the volume of one observer with respect to the other [10]. To assess the ICC 
for each OAR separately, a three-way mixed effect analysis of variance model was applied to 
the volume data. All possible interaction terms were included, with patients and observers 
as random effects and time as a fixed effect. The time effect describes the mean difference 
in volume during the treatment (CTplan vs. CTrep). The patient and time-patient interaction 
effects were considered sources of variation that are unrelated to observer variation. 
Therefore, in line with Barnhart et al. [11], the ICC was calculated as the ratio of the sum 
of variance components for patient and time-patient interaction effects and the sum of all 
variance components. It represents the correlation coefficient of two arbitrary observers 
measuring the same patient at the same time (the same CT scan). We used a classification 
of the data as presented by Shrout et al. [12]. Values of 0.00–0.10 represent virtually no 
agreement (reliability); 0.11–0.40 slight agreement; 0.41–0.60 fair agreement; 0.61–0.80 
moderate agreement; and 0.81–1.00 substantial agreement.
Concordance index
Another endpoint for interobserver variability used in this study was the ratio of the 
intersection (Volume1∩Volume2) and union (Volume1 Volume2) volume of two 
delineated volumes. Terminology for this coefficient varies [13] but we adhered to the term 
concordance index (CI), as is also done in the overview of Hanna et al. [14] and in the review 
of Jameson et al. [15]. The CI is both sensitive to positional differences and differences in 
volume size between observers.
We calculated a mean CI value per OAR by averaging all individual CIs over all ten observer 
pairs and all twelve CT scans, and we determined the range of CIs. A CI of 1.00 indicates 
perfect overlap (identical structures), whereas a CI of 0.00 indicates no overlap at all.
Large discrepancies between the ICC and the CI indicate that observers are either more 
consistent in defining the volume size (ICC>>CI), or more consistent in positioning the 
volumes (CI>>ICC).
3D analysis of variation
The 3D analysis of variation allows quantification of local variation in delineated structures 
in 3D [16]. For each OAR, a median contour surface of all 5 observer delineations was 
computed in 3D [16,17]. The local variation in the five distances to the median (SD) was 
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determined for each surface point, and was averaged over all surface points of the OAR to 
obtain the global 3D SD.
For further analysis, the OARs were divided into several anatomical sub regions. For the 
parotid glands, the upper and lower 5 slices were assigned as the cranial and caudal sub 
region, for the submandibular glands the upper and lower 3 slices were used. The anterior 
and posterior sub regions of the parotid gland were defined to be lateral to the mandibular 
bone. The spinal cord was defined in a cranial (up to C1), medial (C2 to T1) and caudal (from 
T2 on) sub region. The cranial and caudal sub regions of the glottic larynx were defined 
to be the upper and lower slice of the contour, respectively. The cranial sub region of the 
thyroid ended at the point where the median contour consisted of a closed structure in the 
transverse view. The caudal unclosed part of the contour was defined to be the caudal sub 
region. Figure 1 shows a 3D representation of the sub regions (a), together with transverse 
central slices of the OARs (b-f) to illustrate the anterior, posterior, medial and lateral sub 
regions. Calculation of the SD of a particular sub region resulted in a regional 3D SD.
Note that these 3D SD results provided additional information to the ICC and CI, because 





Table 1 and Figure 2 present an overview of the volume data. Variation between observers 
in individual patients as well as between patients was seen. Planning and repeat CT sets 
are depicted separately, but no general trend in the differences between both CT scans 
was observed. For each OAR a certain systematic observer effect in the determination 
of the volumes was seen. Observer 1 and 2 defined significantly smaller volumes for the 
parotid and submandibular glands than the other observers (Friedman Test, p < 0.005). 
For the glottic larynx and spinal cord observer 1 seem to define the smallest volumes while 
observer 5 defines the largest volumes (Friedman Test, p < 0.006). These results were in 
line with the mean OAR ratios (Table 1).
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Division of the studied OARs in sub regions for studying the regional 3D variations in 
delineation. (a) Left side- (left), frontal (middle) and rear (right) 3D view of the studied 
organs at risk (OARs); the parotid and submandibular glands, spinal cord, thyroid cartilage 
and glottic larynx, divided in sub regions according to the colour legend. (b-f) Transverse 
central slices of the parotid gland (b), submandibular gland (c), glottic larynx (d), thyroid 





The CVs in Table 1, which indicate an observer relative standard deviation for observing a 
volume, clearly showed highest variability for the glottic larynx (56%), while the other CVs 
varied from 12 to 16%.
Intraclass correlation coefficient
The ICCs (Table 2) indicated largest observer variation (lowest ICC) in the volumes of the 
glottic larynx (ICC = 0.27) and the spinal cord (ICC = 0.32). Both OARs were classified to 
have slight agreement for delineation of volume sizes. The submandibular glands showed 
fair to moderate agreement (ICC = 0.60 and 0.61) for consistent volume delineation while 
the parotid glands (ICC = 0.65 and 0.86) and the thyroid cartilage (ICC = 0.83) showed 
moderate to substantial agreement.
TABLE 1 
 
Mean volume, coefficient of variance, and mean OAR ratio per observer and organ at risk
OAR Mean volume CV Mean OAR ratio*
[cm3] (SE) obs. 1 obs. 2 obs. 3 obs. 4 obs. 5
Spinal cord 17.6 (1.1) 16% 0.98 0.98 0.91 0.92 1.17
Parotid gland left 28.4 (2.6) 15% 0.92 0.85 1.10 1.08 1.03
Parotid gland right 29.6 (3.9) 12% 0.88 0.90 1.06 1.04 1.02
Submandibular gland left 10.6 (0.9) 16% 1.06 0.86 1.12 1.06 0.95
Submandibular gland right 10.4 (0.9) 16% 1.09 0.88 1.06 1.03 0.90
Thyroid cartilage 11.4 (1.5) 14% 0.96 1.11 1.11 0.97 0.93
Glottic larynx 10.3 (2.8) 56% 0.45 0.60 1.13 1.38 1.66
OAR = organ at risk, SE = standard error of the mean, CV = coefficient of variance, obs. = observer
SE and CV were determined by the results of ANOVA, the CV represents variability due to observers
*OAR ratio = the volume of the OAR as determined by each observer divided by the mean volume  
of all five observers
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FIGURE 2
Variation in the definition of organ at 
risk volume. Volumes of the organs at 
risk according to observer 1(○), 2(□), 
3(×), 4(∆) and 5 (+). CTplan is planning 
CT and CTrep is repeat CT scan. The right 
parotid gland data contains 5 patients 
instead of 6 because of the exclusion of 






Interobserver variability of the organs at risk described by 3 different endpoints




cranial caudal medial lateral anterior posterior
Spinal cord 0.32 0.64 
(0.41–0.83)
1.5 2.1 2.4 0.9 - - -
Parotid gland left 0.65 0.69 
(0.43–0.83)















1.5 2.7 0.8 1.4 1.1 1.4 1.3
Thyroid cartilage 0.83 0.66 
(0.30–0.80)
0.9 1.0 0.9 1.0 0.8 - -
Glottic larynx 0.27 0.37 
(0.11–0.81)
3.9 3.7 5.0 5.0 2.4 - 4.3
OAR = organ at risk, ICC = intraclass correlation coefficient, CI = concordance index and SD =  
standard deviation
Concordance index
The mean CI values varied from 0.64 to 0.71, except for the glottic larynx for which 
the mean CI was 0.37 (Table 2). A large range in the CI of different observer pairs was 
seen (min-max, 0.11–0.86, Table 2).
3D analysis of variation
Largest interobserver variability in the 3D SD evaluation was found for the glottic 
larynx (global 3D SD of 3.9 mm, Table 2). Regional 3D SD values were up to 5.0 
mm for the caudal and medial part of the glottic larynx. Figure 3(d,e,f) illustrates the 
variations in delineation of the glottic larynx for a typical patient CT. Best observer 
agreement was found for the thyroid cartilage (global 3D SD of 0.9 mm, Table 2). For 
all OARs, the regional 3D SD analysis showed largest variations in the cranial regions. 
Furthermore, medial regions tended to show more variation than lateral regions. 
50   CHAPTER 3 - 3D variation in delineation within guidelines
FIGURE 3
Figure 4 illustrates the 3D regional variations of a typical patient for the spinal cord, and for 
a parotid and a submandibular gland. The predominating cranial, caudal and medial parotid 
gland variations can also be seen in Figure 3(a,b,c).
Delineation variation of a parotid gland and a glottic larynx. Left parotid gland 
and glottic larynx delineations in a typical cranial (a and d), central (b and e) and 





This study included an extensive 3D analysis of variation in delineation of a set of OARs 
in the head and neck area. All OARs, except from the glottic larynx, showed moderate 
interobserver variability with ICC values of 0.32–0.83, CI values of 0.64–0.71, and 3D SD 
values of 0.9–2.6 mm. Cranial, caudal, and medial regions of the OARs showed largest 
variations. The glottic larynx showed larger variation in delineation (ICC = 0.27, mean CI = 
0.37 and 3D SD = 3.9 mm). All endpoints provided support for improvement of delineation 
practice.
3D delineation variation of a spinal cord, a right parotid and submandibular gland. 3D Standard 
Deviations (SDs) for a typical patient plotted in colour scale on the median contour surface of the 
organ. Note the different scalings. Spinal cord (a), right parotid gland (b) and right submandibular 
gland (c), frontal view
FIGURE 4
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The inaccurate results for consistency in delineation of the glottic larynx were mainly caused 
by poor compliance to the delineation guidelines. The guidelines prescribe the glottic 
larynx to end at the caudal edge of the cricoid, and to include the arythenoid cartilages 
in the glottic larynx contour. As illustrated in Figure 3 (d,e,f), this description was not 
consistently followed. Reduction of the interobserver variability might be accomplished by 
joint delineation review sessions in which all radiation oncologists who are involved in head 
and neck cancer participate. These sessions are nowadays current practice at our institutes 
(UMCG, NCI-AVL).
The salivary glands showed moderate interobserver variability. Visual inspection of 
the parotid gland contours showed that the guidelines for these organs were also not 
consistently followed. The protocol prescribed that superficial temporal vessels should be 
enclosed in the delineated parotid gland, because they are generally hard to distinguish 
from the parotid gland tissue on scans with no or poor contrast. Still, some observers did 
not include the vessels in their delineation of the parotid gland. Joint delineation review 
sessions and enlightenment of the guidelines could help here. Yi and colleagues [18] for 
instance showed that clear stepwise delineation guidelines resulted in minimal variability. 
Our volume analysis of the parotid gland data showed similar CV values (12 and 15%) as 
data of Geets et al. [19] (17%). Nelms et al. [3] found larger CV values (34% and 29%), 
evaluated for 1 patient by 32 observers. Our 3D SD evaluation reflects valuable information 
on specific regional variations. Largest discrepancies for the parotid glands were located at 
the cranial, caudal and medial sub regions of the gland. For the submandibular glands, the 
cranial parts of the organ clearly showed largest discrepancies. Poor discrimination between 
tissues at the medial borders of the parotid gland (e.g. distinction from the posterior belly of 
the digastric muscle) and the cranial parts of the submandibular gland (e.g. distinction from 
the medial pterygoid muscle and the mylohyoid muscle) could be a reason for these larger 
3D SD values. The addition of MRI might improve the visibility of borders between tissues 
[19,20]. The cranial and caudal variations for the parotid glands could partly be explained 
by the image resolution in the cranial-caudal direction of 2 mm (the slice thickness) and the 
fact that observers could only delineate on transverse CT slices, which limits the resolution 
in both the cranial and caudal part of the delineations. These limitations do, obviously, 
apply to the delineations of all OARs. Possibly the availability of delineation on multiple 
orientations could help to diminish these variations, as is also suggested by Steenbakkers 
et al. [17]. The use of a standardized delineation environment and tools for automatic 
contouring might further contribute to reduce interobserver variability [17,21,22].
Interobserver variability of the spinal cord was predominantly caused by variations at the 
cranial and caudal part of the structure, due to indistinctness of the guidelines and low 
compliance. This problem could be reduced by clearer delineation guidelines although it 
is unlikely that these variations will have major consequences in clinical practice as long 
as the spinal cord is accurately delineated in the vicinity of the irradiated volume and the 
maximum dose to the cord is considered as the leading parameter for treatment planning.
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We analysed the interobserver variability in contouring on twelve CT sets, which consisted 
of six CTplan scans and six CTrep scans. The three endpoints of interobserver variability did 
not indicate a trend in the differences between CTplan and CTrep (for example see Figure 
2). The correspondence of interobserver variability between the scans may suggest that 
the use of contrast (in CTplan) and the use of a(n) (observer specific) delineation template 
(in CTrep) have effects of comparable magnitude on the variation in delineation amongst 
observers, for the considered OARs. Besides, the guidelines are developed to be applicable 
to non-contrast as well as to contrast enhanced CT data, which will minimize possible 
variation in delineation due to (lack of) contrast. According to our experience the addition of 
contrast in delineating OARs is limited, because the uptake of contrast by the selected OARs 
is deniable.
We used different endpoints to quantify interobserver variability in head and neck OAR 
delineation. Variations in volume were indicated by the ICC and differences in combined 
volume and positional variations by the CI. Local variation in delineation was finally 
described by the regional 3D SD. The results showed that the variation in the determination 
of the volume alone (ICC) can be rather large while the combined volume and positional 
variations (CI) did not point to such a large variability (e.g., the spinal cord showed ICC = 
0.32, CI = 0.63). This implies that the variations are situated at the borders of the OAR 
rather than in positional mismatches of the centres of gravity. In another case the ICC 
indicated substantial agreement while the CI was relatively moderate (e.g., the thyroid 
cartilage showed ICC = 0.83 and CI = 0.66), which could indicate a substantial consistency 
in defining volume size while the centre of gravity of the volumes are shifted in position with 
respect to each other. So information of the ICC combined with the CI could help to identify 
the type of interobserver variation (in volume and position). To study variations between 
delineations in detail, the 3D SD provides most complete information.
Some of the endpoints to describe interobserver variability as used in the current study 
have also been applied in studies dealing with head and neck target volume interobserver 
variability. Geets et al. [19] found CVs of 4% and 20% for oropharyngeal and laryngeal-
hypolaryngeal GTVs, which are more or less similar to the CVs we found for OARs (2–16%), 
excluding the glottic larynx (56%). Rasch et al. [20] described 3D SD variability for head and 
neck target volume delineation in the same range as our OAR results; 3.3–4.4 mm for the 
CTV and 4.9–5.9 mm for the elective nodal areas, while our global 3D SD results varied 
from 0.9 to 3.9 mm. Our results thus strengthen earlier findings (e.g. of Nelms et al. [3]) that 
interobserver variability is not only an important issue in the delineation of target volumes 
but also plays a role in the delineation of OARs.
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Conclusion
 
Cranial, caudal, and medial regions of the studied head and neck organs at risk showed 
largest interobserver variability, due to indistinctness of the delineation guidelines, the 
larger image resolution in the cranial-caudal direction, the limitation of delineation on 
transverse slices, and poor discrimination in contrast from adjacent tissues. Potential 
measures to reduce current redundant variability in delineation practice are: (1) guideline 
development, (2) joint delineation review sessions, and (3) application of multimodality 
imaging. Other aspects that could contribute to more consistency in delineation are a 
standardized delineation environment with standard delineation tools, the possibility 
to delineate on multiple orientations and automatic contouring tools. The latter should 
however carefully be validated using base line data of contouring variability such as the 
results of this study. Minor interobserver variability could ultimately benefit radiation 
oncology practice since it may contribute to more general applicability and improvement of 
TCP and NTCP models.
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The objective of this project was to define consensus guidelines for delineating organs 
at risk (OARs) for head and neck radiotherapy for routine daily practice and for research 
purposes.
Methods
Consensus guidelines were formulated based on in-depth discussions of a panel of 
European, North American, Asian and Australian radiation oncologists. 
Results
Twenty-five OARs in the head and neck region were defined with a concise description of 
their main anatomic boundaries. The online Supplemental material provides an atlas of the 
consensus guidelines, projected on 1 mm axial slices. The atlas can also be obtained in 
DICOM-RT format on request.
Conclusion 
Consensus guidelines for head and neck OAR delineation were defined, aiming to decrease 
interobserver variability among clinicians and radiotherapy centers.
 




In recent decades, the quality of radiotherapy imaging, planning and delivery has improved 
markedly. To fully utilize the benefits of these new technologies in radiation oncology 
practice, consistent delineation of targets and OARs has become increasingly important. 
However, delineation accuracy of targets and OARs is limited by interobserver and trial 
protocol variability. By reducing this variability, the generalizability and clinical utility of 
Tumor Control Probability (TCP) and Normal Tissue Complication Probability (NTCP) models 
in routine practice can be improved. To reduce treatment variations among clinicians 
and radiotherapy departments in the delineation of target volumes, guidelines for the 
delineation of the neck node levels for head and neck tumors have been developed [1]. The 
interobserver variability in the delineation of head and neck OARs is similar to the variation 
in the delineation of target volumes [2].
OAR delineation guidelines vary widely between publications and authors, resulting in 
inconsistent dose-–volume reporting [3]. These inconsistencies hamper the comparison 
of dose-–volume effect relationships as reported in studies using different delineation 
protocols [3]. We propose that both daily clinical practice and future multi-institutional 
clinical trials will benefit from improved consistency in delineation guidelines for OARs.
Therefore, the aim of this project was twofold: (1) to attain international consensus on 
the definition and delineation of OARs for head and neck radiotherapy and (2) to present 
consensus guidelines for CT-based delineation of a set of OARs in the head and neck region 
that are considered most relevant for radiotherapy practice.
Methods
 
To reach consensus on OAR guidelines, a panel of experts in the field of head and neck 
radiation oncology was established (WB, CG, VG, AL, PM, CN, JB, SP, DIR, BOS, JAL). The 
panel consisted of representatives from Europe, North America, Australia/ New Zealand and 
Asia and members of the cooperative groups DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC 
CTG, NCRI, NRG Oncology and TROG. For the purpose of this project, a number of group 
meetings were held during international conferences. First, the panel agreed on an OAR 
set considered relevant for the most common acute and late side effects of head and neck 
radiotherapy. We did not discuss dose-–volume effects or side effects for the OAR set in this 
paper, but focussed on a concise description of consensus guidelines for delineation. 
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Second, each member of the panel delineated the OARs in a CT set from one patient 
without any predefined guidelines. The CT images (2 mm slice thickness) were made 
with the patient in a supine position on a multidetector-row spiral CT scanner (Somatom 
Sensation Open, 24 slice configuration; Siemens Medical Solutions, Erlangen, Germany). 
The delineation environment used is dedicated to study interobserver variability [4]. 
Subsequently, the outcome of this procedure was presented to and discussed with the 
experts in order to identify the most prevalent inconsistencies and to formulate consensus 
guidelines. 
Finally, consensus delineations were depicted on axial CT slices of an atlas of head and 
neck anatomy with 1 mm slice thickness. The CT images were registered with T2-weighted 
MRI images of the same anatomy for clarification. Since multimodal imaging is not the 
general standard at present, the atlas description was based on CT only.
Results
 
After the panel delineated the proposed OAR set (Fig. 1), variability in delineation for each 
OAR was discussed. Subsequently, the panel agreed on consensus definitions for each OAR 
and formulated the final consensus guidelines for the following 25 head-and-neck OARs:
Anterior segment of the eyeball
The anterior segment of the eyeball consists of the structures ventral from the vitreous 
humor, including the cornea, iris, ciliary body, and lens.
Posterior segment of the eyeball
The posterior segment of the eyeball is located posteriorly to the lens, and consists of the 
anterior hyaloid membrane and all of the posterior optical structures including the vitreous 
humor, retina, and choroid. The optic nerve is excluded from this contour. The entire retina 
is included in the posterior segment of the eyeball.
Lacrimal gland
The lacrimal gland is located superolateral to the eye and lies within the preseptal space. 
The gland is molded at its inferomedial aspect to the globe, giving it a concave outline. The 
gland can be visualized on CT by its location partly encased in the bone and enveloped in 
low-density fat.
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Parotid glands
The parotid glands were delineated according to previously published guidelines [5]. In 
these guidelines the retromandibular vein is included in the parotid gland contour, since it is 
difficult to discriminate it from the parotid gland tissue in non-contrast enhanced CT images. 
Anatomic borders are listed in Table 1. The use of a planning CT with intravenous contrast is 
however strongly recommended to be able to distinguish the extension of the glands from its 
surroundings.
Submandibular glands
The submandibular glands were delineated according to previous published guidelines [5]. 
Anatomic borders are listed in Table 1.
Extended oral cavity
The delineation of the extended oral cavity was based partly on Hoebers et al. [6]. For the 
sake of simplicity and consistency, the extended oral cavity structure was defined posterior 
to the internal arch of the mandible and maxilla. The mucosa anterior to the mandible and 
maxilla is included in the contour of the lips, and the mucosa lateral to the mandible and 
maxilla is included in the buccal mucosa (see next items and Fig. 3). Anatomic boundaries 
of the extended oral cavity contour are listed in Table 1. For research purposes, the 
extended oral cavity can be subdivided into oral tongue and anterior oropharynx, by drawing 
a vertical line from the posterior hard palate to the hyoid (circumvallate line).
FIGURE 1
Delineation results of 7 
members of the panel 
for the parotid glands, 
spinal cord, pharyngeal 
constrictor muscles and 
the oral cavity, projected 
on an axial CT slice.
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Buccal mucosa
The buccal mucosa is defined according to the borders listed in Table 1.
Lips
The lip contour extends from the inferior margin of the nose to the superior edge of the 
mandibular body. The lip contour was defined to include the lips as well as the inner surface 
of the lips (for delineation details concerning inner surface of the lips refer to Van de Water 
et al. [5]). Detailed anatomic boundaries of the lip contour are listed in Table 1.
Mandible
The mandible was defined as the entire mandible bone, without teeth. The use of CT bone 
view settings is recommended.
Cochlea
The cochlea is embedded in the temporal bone, located lateral to the internal auditory 
meatus, which can best be recognized in CT bone view settings (Fig. 2).
FIGURE 2
Delineation of the cochlea in CT bone settings (left), matched to MRI-T2 (right).
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Pharyngeal constrictor muscles (PCM)
For the delineation of the PCM, many delineation guidelines are available in the literature. 
These are particularly variable regarding the cranial and caudal demarcation [3,7]. For 
the sake of simplicity and reproducibility, we defined the PCM as a single OAR. The cranial 
border was defined as the caudal tip of pterygoid plates (according to previous studies 
[7–12]), and the caudal border as the lower edge of the arytenoid cartilages. For pragmatic 
reasons, a thickness of 3 mm was assumed (Fig. 3).
Supraglottic larynx
The supraglottic larynx is delineated according to Christianen et al. [7]. Anatomic borders 
are listed in Table 1. An axial slice of the supraglottic larynx is depicted in Fig. 4a.
Axial (left) and sagittal (right) view of the consensus delineations of the parotid glands (1), 
pharyngeal constrictor muscles (2), carotid arteries (3), spinal cord (4), mandible (5), extended oral 
cavity (6), buccal mucosa (7), lips (8), brain (9), chiasm (10), pituitary gland (11), brainstem (12), 
supraglottic larynx (13), glottic area (14), crico-pharyngeal inlet (15), cervical esophagus (16) and 
thyroid (17). (For the full atlas, the reader is referred to the online Supplemental material.)
FIGURE 3
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Glottic area
We decided to define the glottic area structure, including the vocal cords and paraglottic fat. 
Air should be excluded from the contour. Cranial, caudal and posterior borders can be found 
in Table 1. An axial slice of the glottic area is depicted in Fig. 4b. 
Arytenoids
The arytenoids (or arytenoids cartilage) are defined as a separate structure. The base 
(caudal edge) of each arytenoid is broad for articulation with the cricoid cartilage. The apex 
(cranial edge) is pointed.
Cricopharyngeal inlet
The crico-pharyngeal inlet represents the transition from the PCM to the cervical esophagus 
(Table 1). An axial slice of the crico-pharyngeal inlet is depicted in Fig. 4c.
Cervical esophagus
The cervical esophagus starts 1 cm caudal to the lower edge of the cricoid cartilage, and 
ends at the caudal edge of C7 (Table 1). An axial slice of the cervical esophagus is depicted 
in Fig. 4d.
Brachial plexus
It is difficult to localize the brachial plexus on CT. Anatomical borders are listed in Table 1, 
and a step-by-step technique, based on the guideline of Hall et al. [14], can be found in the 
online Supplemental Materials.
Thyroid gland
The thyroid gland has two connected lobes and is located below the thyroid cartilage. It has 
considerable contrast compared to its surrounding tissues.
Brain
The delineation of the brain includes brain vessels, and excludes the brainstem. CT bone 
settings are recommended. In the case of nasopharyngeal cancer, a subdivision of brain 
structures could be made, i.e. delineation of the hippocampus and temporal lobe with the 
use of a brain atlas [15,16].
Brainstem
The cranial border of the brainstem was defined as the bottom section of the lateral 
ventricles, the caudal border as the tip of the dens of C2 (cranial border of the spinal cord). 
MRI is recommended for delineation of the brainstem. The bottom section of the lateral 
ventricles is clearly visible on both CT and MRI. For research purposes, the brainstem could 
be further subdivided, for example according to Kocak-Uzel et al. [17].
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Axial CT slices showing the delineation of the supraglottic larynx (A) (a), glottic area (B) 
(b), crico-pharyngeal inlet muscle (C) (c), and cervical esophagus ( D) (d). Other organs at 
risks visible are the submandibular glands ( 1), pharyngeal constrictor muscles (2), carotid 
arteries (3), brachial plexus (4), spinal cord (5), arytenoids (6) and thyroid (7). (For the full 
atlas, the reader is referred to the online Supplemental material.)
FIGURE 4
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Pituitary gland
The pituitary gland is a very small OAR, which in general cannot be identified easily on 
CT. Alternatively, however, the inner part of the sella turcica can be used as surrogate 
anatomical bony structure. The borders of the pituitary gland can be defined best in the 
sagittal view.
Optic chiasm
The optic chiasm is located in the subarachnoid space of the suprasellar cistern. Typically, 
it is located 1 cm superior to the pituitary gland, located in the sella turcica . MRI is 
recommended for delineation of the optic chiasm. It is demarcated laterally by the internal 
carotid arteries and inferiorly to the third ventricle (Fig. 5) [19,20].
Optic nerve
The optic nerve is usually 2–5 mm thick and in general is clearly identifiable on CT [20]. 
It has to be contoured all the way from the posterior edge of the eyeball, through the bony 
optic canal to the optic chiasm. MRI is recommended for a better delineation of the optic 
nerve, at least close to the optic chiasm.
Spinal cord
The spinal cord is delineated as the true spinal cord, not the spinal canal. The cranial border 
was defined at the tip of the dens of C2 (the lower border of the brainstem), and the caudal 
border at the upper edge of T3. With caudally located tumours or lymph node areas, we 
advise extending the spinal cord contours by at least 5 cm caudal to the PTV.
Carotid arteries
The carotid arteries include the common and internal carotid artery (external carotid 
artery was omitted). The left and right common carotid arteries follow the same course 
with the exception of their origin. The right common carotid originates in the neck from 
the brachiocephalic trunk. The left arises from the aortic arch in the thoracic region. The 
bifurcation into the external and internal carotid arteries occurs around the level of C4. The 
upper border of the internal carotid artery is the cranial part of the optic chiasm. 
The resulting consensus delineation guidelines were depicted on 1 mm axial CT slices from 
an anatomy atlas in Mirada RTx (Mirada Medical Ltd., UK) (online Supplemental material). 
The atlas in DICOM-RT format can be retrieved via the different co-operative groups.




With the introduction of these consensus guidelines for delineation of OARs, we aim 
to decrease interobserver variability among clinicians and radiotherapy centers. These 
guidelines complement the previously published guidelines for neck node levels for 
head and neck tumours [1]. These two guidelines combined should contribute to reduce 
treatment variability and should also aid the design and implementation of multi-
institutional clinical trials. The OAR guidelines are particularly useful when radiation-induced 
side effects are considered relevant endpoints. Moreover, the current consensus guidelines 
could facilitate the generalizability and clinical utility of Normal Tissue Complication 
Probability (NTCP) models. 
FIGURE 5
Delineation of the optic nerves (blue and purple), optic chiasm (green) and carotid arteries 
(yellow and brown) on CT (left) and MRI-T2 (right). (For interpretation of the references to 
color in this figure legend, the reader is referred to the web version of this article.)
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We decided not to describe all possible OARs in great detail. Consequently, for some 
OARs we did not use single anatomic structures, but amalgamated surrogate structures 
involved in combined functions (e.g. the extended oral cavity). Nevertheless, the current 
guideline contains a comprehensive list of OARs. At the individual patient/center level one 
should decide which OAR to include, a decision that may depend on the tumour location, 
for example. In general, it is helpful to always include the delineation of the parotid and 
submandibular glands, spinal cord and PCM. For research purposes, OARs could be further 
subdivided (e.g. as described in case of the extended oral cavity, PCM, brainstem and brain). 
There are natural variations for some OARs, such as the location of the bifurcation of the 
common carotid artery [21], which is used for contouring the brachial plexus. In addition, 
anatomic changes in OARs may occur due to tumor extension, or an OAR may be infiltrated 
by tumor. Therefore, a basic understanding of the normal anatomy remains essential. 
For primary tumors of the nasopharynx, oral cavity and oropharynx, we strongly recommend 
the use of MRI in addition to CT. This will facilitate the delineation of OARs in this area, 
which includes the brainstem, spinal cord, pituitary gland, lacrimal glands, optic chiasm and 
optic nerves. MRI is ordinarily also beneficial for delineation of the parotid glands and PCM. 
For primary tumors in close vicinity of the brain, we also recommend defining the temporal 
lobe and hippocampus (but delineation guidelines for these OARs are beyond the scope of 
these current guidelines) [15,16]. 
Some of the atlas structures are very small, such as the cochlea, pituitary gland, lacrimal 
glands and chiasm, with volumes <0.5 cm3. Volume and dose–volume histogram (DVH) 
data calculated over such small volumes is susceptible to differences in the calculation 
algorithm (i.e. sampling and interpolation strategy), and also depend on CT slice thickness, 
pixel width, dose grid voxel width and DVH dose resolution, and may differ widely between 
the various methods [22]. Consequently we recommend expanding small structures such as 
the cochlea, pituitary gland, chiasm and arytenoids by 5 mm to calculate reliable and more 
consistent DVH data (but avoid overlap with the PTV). Additionally, we recommend acquiring 
constrast-enhanced CT scans with ≤ 2mm slice thickness to improve delineations of such 
very small structures. 
For some, serial OARs, ICRU recommends the addition of a PRV margin, which depends 
on planning technique and patient population [23]. For the spinal cord for example, it is 
common practice to add a 5mm PRV margin [24]. In the case of OARs in close proximity to, 
or overlapping with the PTV, derived OAR structures can help to guide the planning process 
(i.e. OAR with subtraction of the PTV). For dose evaluation, however, the original OAR contour 
should be used. We advise to adhere to the standardized OAR naming conventions as 
proposed by Santanam et al. [25]. 
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We recommend incorporating the current guidelines on a large scale to support consistent 
reporting of dose–volume data in addition to encouraging consistent radiotherapy practice 
for treatment prescriptions.  Considering the increasing use and availability of MRI as well 
as the increasing knowledge and understanding about the OARs that are most relevant for 
side effects in radiotherapy, we anticipate updating these recommendations in the near 
future to a full MRI-based delineation guideline, incorporating as much anatomical and 
functional information as possible.
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Abstract
Background
The last decade, many efforts have been made to characterize anatomic changes of head 
and neck organs at risk (OARs) and the dosimetric consequences during radiotherapy. This 
review was undertaken to provide an overview of the magnitude and frequency of these 
effects, and to investigate whether we could identify criteria to identify head and neck 
cancer patients who may benefit from adaptive radiotherapy (ART). Possible relationships 
between anatomic and dosimetric changes and outcome were explicitly considered. 
Methods
A literature search according to PRISMA guidelines was performed in MEDLINE and EMBASE 
for studies concerning anatomic or dosimetric changes of head and neck OARs during 
radiotherapy. 
Results
Fifty-one eligible studies were found. The majority of papers reported on parotid gland (PG) 
anatomic and dosimetric changes. In some patients, PG mean dose differences between 
planning CT and repeat CT scans up to 10 Gy were reported. In other studies, only minor 
dosimetric effects (i.e. <1 Gy difference in PG mean dose) were observed as a result of 
significant anatomic changes. Only a few studies reported on the clinical relevance of 
anatomic and dosimetric changes in terms of complications or quality of life. Numerous 
potential selection criteria for anatomic and dosimetric changes during radiotherapy were 
found and listed. 
Conclusions
The heterogeneity between studies prevented unambiguous conclusions on how to identify 
patients who may benefit from ART in head and neck cancer. Potential pre-treatment 
selection criteria identified from this review include tumour location (nasopharyngeal carci-
noma), age, body mass index, planned dose to the parotid glands, the initial parotid gland 
volume, and the overlap volume of the parotid glands with the target volume. These criteria 
should be further explored in well-designed and well-powered prospective studies, in which 
possible relationships between anatomic and dosimetric changes and outcome need to be 
established.




Radiotherapy  is a commonly applied treatment modality in head and neck cancer patients. 
Intensity modulated radiotherapy treatment plans with steep dose gradients are currently 
considered standard. These treatment plans are constructed on planning CT images, 
acquired prior to the start of radiotherapy. To account for patient positioning errors relative 
to these planning CT images, position verification procedures are generally applied during 
the course of radiotherapy. However, because of different patient postures and anatomic 
changes during the course of radiotherapy, the dose actually given to the patient can 
deviate from the planned dose [1]. These dose differences may lead to underdosage to 
target volumes and/or overdosage to organs at risk (OARs) [2]. 
Radiation-induced complications have a significant adverse impact on health-related quality 
of life [3]. Hence, it is important to monitor radiation doses to OARs during treatment. This 
is particularly salient in the head and neck area, where OARs are in close proximity to target 
volumes. However, at present, verification of the dose actually given to the patient is not 
considered routine clinical practice. Adaptive radiotherapy (ART) could be applied to reduce 
dose to OARs and eventually to improve quality of life [4–8]. ART is a formal approach 
to correct for daily tumour and normal tissue variations through streamlined online or 
offline modification of original target volumes and plans [9, 10]. Implementation of ART 
is challenging both from clinical and logistic points of view and generally requires many 
resources. Clear guidelines are needed on the timing of rescanning and replanning, and an 
increasing amount of data needs to be acquainted, handled, transferred and stored. It is 
unlikely that every patient will benefit from ART and therefore tools to select patients who 
are expected to benefit most from plan adaptation during treatment become increasingly 
important [11].
In previous studies, it was shown that anatomic changes cause more dose deviations in 
OARs than in target volumes [12–15]. Clinical target volume (CTV) coverage is usually more 
robust to changes because of the use of the PTV concept, while planning volumes at risk 
(PRV) margins are generally applied for spinal cord and brain stem, but are not common 
practice for all OARs.  Only 13% of the studies in this review reported PRV margins around 
the spinal cord and/or the brainstem [4, 5, 11, 16–18], and only 4% of the studies reported 
on PRV margins for all OARs [5, 16]. In addition, position verification mainly focuses on 
correcting for set-up errors of targets, and for that reason might lead to increased doses to 
distant OARs. Therefore, it is expected that the largest gain of ART would therefore be the 
monitoring and reduction of the dose to OARs. 
For a strategic selection of patients who may benefit from adaptive strategies, identification 
of selection criteria that are associated with dosimetric changes and resulting complications 
is necessary. Patient selection for ART can be realized by selection prior to treatment, 
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i.e. based on pre-treatment characteristics, and by selection during treatment based on 
geometric and/or dosimetric changes early in treatment, either by non-imaging related 
factors (e.g. weight loss)  or by imaging related factors (e.g. density changes).
Castadot et al. [19] have summarized the results of seven studies reporting on anatomic 
modifications of head and neck target volumes and OARs during radiotherapy in 2010. The 
authors concluded that radiotherapy induces major volumetric and positional changes in 
CTVs and OARs during treatment. Parotid glands tend to shrink and to shift medially towards 
the high dose region, potentially jeopardizing parotid sparing [19]. Not all of these studies 
reported to what extent these anatomic changes actually translate into dosimetric changes. 
Furthermore, no unambiguous effect of anatomic changes on dose has been found. Since 
2010, the amount of studies reporting on anatomic and dosimetric changes has increased 
dramatically.
The main objective of this review was to evaluate the current literature on anatomic and 
dosimetric changes of head and neck OARs during radiotherapy. Furthermore, implications 
of these changes for the rate and severity of complications and quality of life were reported. 
In addition, we tried to identify selection criteria for changes during radiotherapy and 
recommended on the conduction of further studies on this subject. Results of this review 




We performed a literature search in MEDLINE and EMBASE according to PRISMA guidelines 
[20] using the following keywords: ((synonyms for anatomic changes) OR (synonyms for 
dosimetric changes)) AND (synonyms for organs at risk) AND (synonyms for head and neck 
radiotherapy). The search was completed by March 1, 2015.
In addition, reference lists of papers were screened in order to retrieve additional relevant 
papers. Both prospective and retrospective studies published in journals part of the 
Thomson Reuters journal citation reports® were included. Studies in languages other than 
English, and studies only available in abstract form were excluded from this review. 
Studies had to fulfil the following eligibility criteria to be selected for this review:  
• report on anatomic and/or dosimetric changes of adult head and neck organs at risk  
 during the course of photon radiotherapy, and 
• at least ten patients included.
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We present overviews of anatomic changes, dosimetric changes, and report potential 
selection criteria of either one. In addition, we report on studies describing the effects of  
anatomic and dosimetric changes during radiotherapy on side effects and quality of life. The 
results are presented by volume changes in percentages and dose changes in Gray in order 
to make comparisons across studies easier to interpret. Associations are presented in five 
ways; by the Pearson correlation coefficient (R), the coefficient of determination (R2), the 
Spearman’s rank correlation coefficient (ρ), linear regression analysis (r or r2), and by the 




Figure 1 presents the outcome of the search strategy. Fifty-two potentially eligible records 
were found in MEDLINE and EMBASE, and forty-four additional papers were extracted from 
reference lists. We excluded twenty-eight records as they were conference abstracts,  two 
studies because only the abstract was available [21, 22], and two papers because their 
journal was not part of the Thomson Reuters journal citation reports® [23, 24]. Furthermore, 
three papers were excluded as they were general reviews on image guided radiotherapy 
(IGRT) and ART [9, 19, 25]. Eventually, sixty-one full text articles were assessed for eligibility. 
Five of these papers did not meet the eligibility criteria since they reported on other subjects 
and five papers included less than ten patients [26–30]. Hence a final number of fifty-one 
studies could be included in the analyses for this review [2, 4–7, 11–18, 31–68].  
Reported organs at risk
In the fifty-one original studies at least one of the following organs at risk was 
included in the analysis: the parotid gland (PG), submandibular gland, spinal cord, 
spinal canal, brainstem, mandible, oral cavity, larynx, pharyngeal constrictor muscles, 
sternocleidomastoid muscles, masticatory muscles, masseter muscles, medial pterygoid 
muscles, thyroid gland, optic chiasm, optic nerve, eyeball and lens.
Timing and frequency of imaging during radiation treatment
OARs were assessed on different time points during radiotherapy (tenth fraction to end 
of treatment, see also Figure 2, Table 4-6) mainly by cone beam CT (CBCT), helical repeat 
CT and megavoltage CT (MVCT), but also by in-room CT [14, 17, 44, 51] and MR imaging 
[52]. Two studies applied repeat MR imaging in addition to the repeat CT scans [15, 16]. 
In most studies, the re-delineation of OARs was performed manually or automatically 
using deformable image registration (DIR) with visual inspection and manual corrections if 
needed. The frequency of imaging varied between studies. Most of the studies reported on 
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multiple time points during radiotherapy. Fourteen studies performed at least weekly repeat 
imaging [7, 12, 17, 18, 37, 43–46, 51, 53, 62, 63, 65]. Three of these studies had daily 
MVCT imaging at their disposal [18, 45, 46], and one performed daily in-room CT imaging 
[7]. If results of multiple time points were reported, anatomic and dosimetric changes from 
the last time point were included in this review. 
The authors of the different studies reported a variety of time points during treatment 
that could be optimal for re-scanning and re-planning. There are several indications that 
anatomic changes are more pronounced in the first half of treatment, and therefore 
re peated imaging and replanning should be performed in this first time period [34, 60,  
62, 65]. 
FIGURE 1
PRISMA flow diagram of literature search.
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FIGURE 2
(a) Parotid volume loss vs. patient’s weight loss (22 studies),  (b) parotid mean dose 
increase (repeat CT - plan CT) vs. weight loss (16 studies) , (c) parotid volume loss vs. 
planned parotid mean dose (20 studies) , and (d) parotid mean dose increase (repeat CT - 
plan CT) vs. parotid volume loss (23 studies) during radiotherapy. The size of the data points 
is proportional to the number of patients included in the study (minimum 10, maximum 87 
patients). fx= fraction, tx= treatment. Time point: time of the repeat scan analysed.
Author Time point
1. Ahn et al. [31] fx 11 (mean)
2. Bhide et al. [34] end of tx
3. Capelle et al. [36] fx 15
4. Castadot et al. [11] fx 20-25
5. Chen et al. [15] end of tx
6. Cheng et al. [16] fx 25
7. Duma et al. [38] fx 25
8. Duma et al. [13] fx 16 (median)
9. Fung et al. [41] fx 30-35
10. Hansen et al. [2] fx 29 ± 9
11. Height et al. [42] fx 20-25
12. Ho et al. [43] fx 25-30
13. Jensen et al. [44]  fx 5-35
14. Lee et al. [46] end of tx
15. Marzi et al. [48] end of tx
16. Nishi et al. [4] fx 10-20
17. Robar et al. [17] end of tx
18. Wang et al. [59] fx 18
19. Wu et al. [12] fx 25-30
20. Zhao et al. [6] fx <20
21. Ajani et al. [32] fx 25-30
22. Barker et al. [33] end of tx
23. Broggi et al. [35] end of tx
24. Lu et al. [47] fx 20
25. Richetti et al. [53] fx 30-35
26. Sanguineti et al. [62] fx 16(median)
27. Vasquez et al. [57] fx 23
28. Wang et al. [60] end of tx
29. Cozzolino et al. [66] fx 25
30. Hunter et al. [65] end of tx
31. Castelli et al. [63] fx 25-30
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Anatomic and dosimetric changes
Twenty-six papers described both anatomic and dosimetric changes during the course of 
radiation [2, 4, 6, 11–13, 15–17, 31, 34, 36, 38, 39, 41–44, 46, 48, 54, 59, 61, 63, 65, 
66]. Two studies reported on dosimetric changes without referring to anatomic changes [18, 
51]. Twenty studies described the relationship between several parameters and anatomic 
and/or dosimetric changes [4, 7, 11, 31–33, 35, 36, 40, 43, 46, 48, 57, 59, 60, 62–65, 
68] (Table 1 and 2). Twelve studies reported on the association between anatomic and 
dosimetric changes with complications and quality of life [5–7, 48, 50, 54, 55, 61, 63, 65, 
67, 68] (Table 3). In two of these studies, a significant reduction of side effects was found 
when replanning was performed vs. no replanning [5, 6]. The findings of specific changes 
during radiotherapy and the corresponding correlations and associations are summarized 
per organ in the next paragraphs.
1. Parotid gland
The majority of the studies included anatomic and/or dosimetric changes of the parotid 
glands (PGs). This interest for PG changes during radiotherapy can be explained by the 
fact that radiation dose to the PGs was associated with reduced saliva production [69] and 
xerostomia [70, 71].
When all studies were taken into account, the average volume decrease of the PGs during 
radiotherapy was 26 ± 11% (note: volume loss reported on different time points during 
radiotherapy, Table 4). Some studies presented the PG shrinkage rate per treatment day or 
treatment week [15, 33, 37]. Sanguineti et al. [62] studied weekly CT scans of eighty-five 
patients and concluded that the PG shrinkage is not linear (PGs shrunk most during the first 
half of treatment). 
Thirty-eight papers reported on PG anatomic changes [2, 4, 6, 7, 9, 12, 13, 15–17, 31–45, 
47, 48, 50, 53, 56, 57, 59, 60, 62–66]. The most common reported anatomic changes 
were volume loss (Table 4) and medial shifts of the PGs [17, 32–34, 37, 42, 44, 45, 48, 51, 
57, 59, 64]. Jensen et al. [44] found a medial, cranial, and dorsal shift of the PG centre of 
mass from its original position. In general, a medial shift was observed of the medial and 
lateral aspects of both PGs [4, 17, 32, 48, 57]. Vasquez-Osorio et al. [57] reported on shape 
and position changes of six sub-regions of the PG. The medial translation of the inferior 
region of the irradiated PGs was similar to that of the lateral region (3±4 mm). Fiorino et al. 
[40] and Belli et al. [67] found reduced PG densities during IMRT.  
Twenty-four papers reported on dosimetric changes of the PGs [2, 4, 6, 11–13, 15–18, 
31, 34, 36, 38, 41–44, 46, 48, 51, 59, 65, 66]. On average, the PG mean dose increased 
with 2.2 ± 2.6 Gy as compared to the dose calculated on the planning CT at baseline. Not 
all papers reported on absolute dose values. The studies that reported the highest dose 
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increase consisted of (a majority of) (naso)pharyngeal carcinoma patients [4, 6, 15, 16, 34, 
46, 58]. The largest PG dose increase was found by Chen et al. [15] and Cheng et al. [16] 
(on average mean dose increase of 10.4 Gy in the sixth week of radiotherapy, and median 
dose increase of 7.8 Gy at the twenty fifth fraction, respectively). Both prospective studies 
included stage III-IV nasopharyngeal carcinoma patients. 
1.1. Factors correlating with parotid gland volume loss and parotid  
mean dose increase
Eighteen studies reported on factors that correlated significantly with PG anatomic and/
or dosimetric changes (Table 1). The most frequently reported factors were weight loss, PG 
dose and PG volume loss. All data available is presented in Figure 2. On average, no clear 
relation between these factors and changes was found. The strongest association found 
was between PG dose and PG volume loss; three of the larger studies (more than eighty 
patients included) reported a significant correlation of PG dose with PG volume loss [35, 60, 
62]. Still, large variety of volume loss was observed between studies (Figure 2c).
Table 1 includes all factors that demonstrated significant correlations (p<0.05) with 
corresponding correlation/association measures.
1.2. Anatomic and dosimetric changes of the parotid gland and outcome
Significant associations between PG volume change and the occurrence of complications 
were found in five studies [7, 48, 55, 67, 68] (Table 3). In general, more PG shrinkage was 
associated with higher complication rates [48, 67]. On the contrary, Sanguineti et al. [68] 
observed that the patients who received mean doses over 35.7 Gy to the PG developed 
more physician-reported GR2+ xerostomia if the shrinkage of the combined volume of 
parotid glands was lower than 19,6%. Nishimura et al. [50] found out that the patients with 
initially small parotid glands (≤ 38.8 ml) had significantly more severe xerostomia three 
to four months after the start of IMRT than patients with initially larger parotid glands (p= 
0.040), while the correlation between the shrinkage of PG and the grade of xerostomia 
was not significant (p= 0.186) (Table 3). Belli et al. found that apart from volume decrease, 
also early density decrease was associated with significantly higher acute xerostomia 
scores (Table 3). Weight loss >5% and/or decrease of neck diameter >10% was associated 
with higher xerostomia scores in the study of You et al. [61]. Hunter et al. concluded that 
dosimetric changes were small relative to the standard deviations of the dose and saliva 
flow data [65].
Yang et al. [5] studied global quality of life in addition to the different side effects for IMRT 
replanning vs. no replanning, and reported better quality of life and less side effects for the 
IMRT replanning group (Table 3).
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TABLE 2
Studies reporting on parameters associated with contour reduction (anatomic endpoints) 
and dosimetric changes of spinal cord and mandible (dosimetric endpoints) during the 
course of radiotherapy. Only statistically significant correlations are shown. Results of 
Spearman correlation were denoted with ρ, Pearson correlation with R.
2. Submandibular glands
In contrast to the parotid glands, information on anatomic and dosimetric changes of the 
submandibular glands is scarce. On average, a submandibular gland volume reduction 
of 22% (15-32%) was found [37, 57, 60]. Wang et al.[60] found a significant correlation 
between the planned submandibular gland dose (r=0.389, p<0.001) and submandibular 
gland volume reduction, while no such correlations were found by others [57]. Irradiated 
submandibular glands tend to move superiorly, in particular the caudal and lateral 
sub-regions with displacements of on average 3-4 mm [57]. Similar results were found by 
Castadot et al. [11]. These authors also observed superior as well as medial shifts of the 
submandibular glands. In this study, the mean approximated actually delivered doses to 
the submandibular glands increased compared with the planned doses (52.8 vs. 51.9 Gy) 
(Table 6). 
3. Brainstem and spinal cord
A number of authors reported on changes in maximum doses or D1% to the brainstem [2, 
6, 15, 16, 18, 31, 34, 41–43, 59] and the spinal cord [2, 6, 11, 13, 15, 16, 18, 31, 34, 36, 
41–43, 59, 66] during the course of treatment (results are listed in Table 6). Zhao et al.[6] 
found the highest dose increase in D1% of the spinal cord and the brainstem of on average 
0.20 and 0.09 Gy per fraction, which would result in an accumulated excess dose of 5.6 
and 2.5 Gy, respectively, for the entire treatment course. Cheng et al. [16] reported that if 
no replanning was performed, for 11% and 16% of the patients the tolerance dose of 54 Gy 
for the maximum dose to the brainstem was exceeded after 30 and 50 Gy, respectively, and 
for 11% of the patients the maximum dose to the spinal cord was higher than 45 Gy after 
both 30 and 50 Gy.
3.1. Factors correlating with brainstem and spinal cord dose increase
A number of variables correlated significantly with an increase in dose parameters (D2%, 
Dmax) to the spinal cord, including changes in GTV volume, weight loss, change in neck 
diameter at the level of the thyroid notch and a few other anatomic, CT related variables 
(Table 2).
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Studies reporting on parotid volume loss during the course of radiotherapy. Pts= patients, 
fx= fractions, ipsi= ipsilateral, contra= contralateral, - = not reported.
TABLE 4
Study # Pts Mean Parotid volume loss Time point Weight loss Correlation Parotid 
volume loss – 
Weight loss?
Nishimura et al. [50] 33 26% (bilateral volume) 10-20 fx - -
Nishi et al. [4] 20 18% 10-20 fx - -
Ahn et al. [31] 23 24% 11 fx (mean) mean 8% YES
Capelle et al. [36] 20 20% 15 fx mean 5% -
Duma et al. [13] 11 18% (left) and 2% (right) 16 fx (median) median 3% NO
Sanguineti et al. [62] 85 32% 16 fx (median) median 9% YES
Schwartz et al. [7] 24 16% 16 fx (median) - YES
Wang et al. [59] 15 ~20% 18 fx median 8% YES
Zhao et al. [6] 33 7% (ipsi) and 1% (contra) < 20 fx - -
Lu et al. [47] 43 36% 20 fx mean 13% NO
Castadot et al. [37] 10 23% (contra) and 20% 
(ipsi)
20-25 fx - -
Height et al. [42] 10 median 24% (contra) and 
21% (ipsi)





10 17% (irradiated) and  
5% (spared) 
23 fx - -
Duma et al. [38] 10 14% 25 fx mean ~6-8% NO
Cheng et al. [16] 19 28% (ipsi) and  
13% (contra)
25 fx mean 9% -
Cozzolino et al. [66] 10 34% (ipsi) and 40% 
(contra)
25 fx mean 5% NO
Wu et al. [12] 11 14% 25-30 fx - -
Ho et al. [43] 10 28% (ipsi) and 25% 
(contra)
25-30 fx mean 8% YES
Ajani et al. [32] 13 36% 25-30 fx median 7% YES
Castelli et al. [63] 15 28% 25-30 fx - -
Hansen et al. [2] 13 19% 29 ± 9 fx 4-14% (range) -
Richetti et al. [53] 26 29% 30-35 fx median 11% -
Fung et al. [41] 10 33% 30-35 fx - -
Barker et al. [33] 14 median 28% end of treatment median 7% -
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Study # Pts Mean Parotid volume loss Time point Weight loss Correlation Parotid 
volume loss – 
Weight loss?
Robar et al. [17] 15 ~30% end of treatment mean 8%, 
median 7%
-
Lee et al. [45] 10 median 21 % end of treatment median 3% -
Wang et al. [60] 82 27% end of treatment - -
Bhide et al. [34] 20 ~35% end of treatment mean 10% -
Broggi et al. [35] 87 26% end of treatment median 8% YES
Chen et al. [15] 20 45% end of treatment - -
Fiorino et al. [40] 84 ~30% end of treatment - -
Fiorentino et al. [39] 10 58% (ipsi) end of treatment - -
Marzi et al. [48] 15 41% end of treatment mean 7% -
Schwartz et al. [14] 22 26% end of treatment - -
Hunter et al. [65] 18 Median 13% end of treatment median 6% -
Tomitaka et al. [56] 15 29% 2 wk post 
treatment
- -
Jensen et al. [44] 72 median 43% (ipsi) and 
36% (contra)
5-35 fx median loss of 
volume 7%
-
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Studies reporting on anatomic changes of other organs at risk. Pts= patients, (C)RT= 
(chemo)radiotherapy
TABLE 5
Study # Pts Organ Anatomic change Time point
Volume change (%)
Cozzolino et al. [66] 10 larynx +14.9 25th fraction
   Muscle area change,  
high dose side (%/year)
 








>1 year post RT
 
> 50 Gy: thickness 
change (%)




3 months post 
CRT
 
  Volume change (%)  















Studies reporting on dosimetric changes of submandibular glands, spinal cord, brainstem 
and other organs at risk.
TABLE 6
Study # Pts Organ Dosimetric change 
dose difference repeat 
imaging - planning (Gy)
Time point











end of treatment (week 5)
Capelle et al. [36] 20 spinal cord  Dmax +0.2 15th fraction
Castadot et al. [11] 10 submandibular gland Dmean














end of treatment (week 6)
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Study # Pts Organ Dosimetric change 
dose difference repeat 
imaging - planning (Gy)
Time point




optic chiasm  Dmax
optic chiasm  D1%
ipsilateral optic nerve  Dmax
ipsilateral optic nerve  D1%
contralateral optic nerve  Dmax
contralateral optic nerve  D1%
ipsilateral eyeball  Dmax
ipsilateral eyeball  D1%
contralateral eyeball  Dmax
contralateral eyeball  D1%
ipsilateral lens  Dmax
ipsilateral lens  D1%
contralateral lens  Dmax
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fractions of MVCBCT






























Ho et al. [43] 10
 
spinal cord  Dmax
brainstem  Dmax 
+1.1
+0.3 
average variation in 
dose across weeks 1-6 
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4. Other organs at risk
The results of studies regarding anatomic and/ or dosimetric changes of the larynx, 
masseter muscle, medial pterygoid, pharyngeal constrictor muscles, sternocleidomastoid 
muscles, masticatory muscles, thyroid gland, mandible, submandibular glands, oral 
cavity, optic chiasm, optic nerve, eyeball, lens and cochlea  are listed in Tables 5 and 
6, respectively [2, 11, 13, 16, 18, 31, 49, 52, 53, 66]. Clear swelling of the larynx and 
pharyngeal constrictor muscles was found by Ricchetti et al. [53] at week seven of 
radiotherapy. Swelling of the larynx was also reported by Cozzolino et al. [66], five weeks 
after the start of radiotherapy. Popovtzer et al. [52] observed a thickness change of +111% 
in parts of the pharyngeal constrictors that received more than 50 Gy, three months post 
chemoradiation. However, the thickness and volume of the sternocleidomastoid muscles 
decreased [52, 53].
In most publications, only small changes in the mean dose (< 1 Gy) to  organs at risk during 
the course of radiotherapy have been reported [11, 13, 18] (Table 6). Dosimetric changes 
to e.g. the mandible are more often caused by head rotation instead of anatomic changes 
[12]. In contrast, a rather large increase in maximum and D1% was found by Cheng et al. 
[16] for some organs after 30 and 50 Gy, with the largest dose increase for the optic nerves 
after 50 Gy (Dmax increase from 48.5 ± 4.5 to 56.3 ± 5.0 Gy (ipsilateral) and from 26.7 ± 
16.1 to 36.9 ± 20.8 Gy (contralateral) (mean ± SD)) (Table 6). This means that for individual 
cases, the maximum dose to the optic nerve could have been > 60 Gy if no replanning was 
performed, with a markedly increased risk of toxicity as a consequence [72].
Discussion
 
This is the first review that focused on anatomic and dosimetric changes of head and neck 
organs at risk during the course of radiotherapy and on the correlation of these changes 
with side effects. In total, fifty-one papers on this subject were identified according to the 
PRISMA methodology [20].
The parotid gland was the most studied OAR and showed the largest volume changes 
during radiotherapy (26% average volume decrease). The dosimetric consequences of PG 
shrinkage varied widely, with on average a PG mean dose increase of 2.2 ± 2.7 Gy. Only a 
few studies investigating volume changes of the submandibular glands were found. This 
could be explained by their location, encompassed by neck lymph node level IB and in close 
proximity to the frequently irradiated neck lymph node level II. This complicates their sparing 
and results in high initial submandibular gland doses, possibly less sensitive for dosimetric 
variations.
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Introduction of adaptive radiotherapy
ART for head and neck patients is currently subject to many studies. Theoretically, ART could 
be performed by adapting treatment plans to the actual patient anatomy on a daily basis. 
Yan and Liang showed in a retrospective planning study of nineteen patients that weekly 
adaptive inverse planning optimisation already improved the dose distribution of head and 
neck cancer treatment significantly [8]. Chen et al. [73] suggested from their retrospective 
study that for appropriately selected patients the theoretical benefits i.e. improved dose 
distributions of ART may be associated with actual clinical advantages. The authors also 
concluded that routine replanning is probably not necessary. This is confirmed by our own 
experience, based on weekly repeat CT scans, showing that in less than 20% of all head and 
neck patients replanning was needed because of target underdosage or OAR overdosage, 
usually during the first three weeks of treatment (personal communication).
Only limited data is published so far on the effect of dosimetric changes on  the occurrence 
of side effects or quality of life (current review, Table 3). The optimal frequency and utili-
zation, as well as the ultimate clinical impact of ART still remain to be determined [9, 14, 
25]. There are several indications that anatomic changes are more pronounced in the first 
half of treatment, and therefore repeated imaging and replanning should be performed in 
this first time period [34, 60, 62]. Schwartz et al. [14] conducted a prospective clinical trial, 
and concluded that properly timed replanning could result in dosimetric improvement, but 
that the clinical impact of ART remains to be confirmed. Dawson and Sharpe [25] stated 
that increased precision and accuracy of radiotherapy are expected to augment tumour 
control and reduce the incidence and severity of toxic effects after radiotherapy. On the 
other hand, they mentioned that the desire for sub-millimetre technical precision needs to 
be balanced with risk of chasing only modest clinical gains and the possibility of imposing 
an unacceptable workload on radiotherapy planning, delivery, and review processes. There 
are limited resources at most radiotherapy departments, and identification of patients 
that benefit from ART would restrict the workload tremendously and thus would be more 
cost-effective. Results of future prospective clinical trials linking anatomic and dosimetric 
changes to outcome are needed to confirm the clinical impact of ART.
Application of selection criteria for ART
The potential selection criteria for PG volume loss identified in the current review that 
may improve the selection of patients for ART prior to treatment were tumour location 
(nasopharyngeal carcinoma), age, body mass index, planned dose to the parotid glands, the 
initial parotid gland volume, and the overlap volume of the PG with lymph node metastases. 
PG volume loss is in this case presumed to result in higher complication rates ([48, 55, 67],  
Table 3). This could be due to an increase in PG dose, or to a direct relationship between 
PG volume and complications [67, 68]. For the majority of patients, PG volume loss resulted 
in an increase of the mean dose to the PGs (Figure 2d). However, we could not confirm a 
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clear association between volume loss and mean dose increase (Figure 2d). This can be 
explained by the fact that the treatment plan and consequential dose distribution depend 
on many factors such as the location of the boost volume.
Apart from selection of patients prior to treatment, selection during treatment could be 
performed, based on either detected changes or by parameters related to these changes. 
Weight loss, change in body thickness, reduction of lateral neck diameter, PG volume 
decrease, PG density decrease, distance between PG centres of mass and GTV volume 
decrease turned out to be potential selection criteria for either PG volume loss, increase of 
the PG dose and/or differences in the degree of side effects (Tables 1 and 3). Considering 
the other OARs, weight loss and GTV volume decrease during radiotherapy positively 
correlated with the maximum dose to the spinal cord (Table 2), and lateral dimension 
changes at beam axis correlated well with the degree of mucositis [54]. 
The difficulty with most of the potential selection criteria found in this review to select 
patients for ART is that although statistical significant associations were found with 
ana tomic and/or dosimetric endpoints, these were generally weak (Tables 1 and 2). More-
over, most potential selection criteria resulted from correlation tests, although regression 
analysis is more suitable to investigate the predictive power. Furthermore, some authors 
reported Pearson correlation coefficients, although normal distribution of the data and 
the linear relationship between variables wasn’t proven. If a non-linear but monotonic 
relationship between variables is observed, the Spearman correlation should be used. 
To enable proper selection of patients for re-planning, multivariable prediction models are 
needed, derived from sufficiently powered prospective study populations. Most studies 
in this review consisted of limited patient populations and were therefore not suitable 
for model development. The performance of such models should be sufficient to identify 
patients that need ART with high sensitivity and specificity. 
Bias in individual studies
It is likely that the large heterogeneity in results as depicted in Figure 2 can be explained 
by differences between study designs, such as different patient and tumour characteristics 
(localization, staging), differences in timing of repeated imaging, treatment (combination 
with surgery / chemotherapy), treatment technique (IMRT or tomotherapy), margins, specific 
settings of the radiotherapy treatment planning, and patients’ nutritional status.
Another problem in the comparison of the results of the different studies is that different 
types of analysis were used, and results were reported in different quantities (e.g. volume 
changes in % or cm3, dose changes in % of prescribed dose or in Gy). Also, individual 
patient data and standard deviations of the differences were often lacking. These 
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afore mentioned differences in study design and the variation in methods of analysis 
and reported quan tities are one of the most common problems in systematic reviews 
of prog nostic studies [74]. It is therefore not possible to perform a meta-analysis, but it 
is a strong argument in favour of systematic reviews [74]. On the individual study level, 
random allocation of patients is seldom performed. Often, detailed study inclusion criteria 
are lacking, and some of the studies are retrospective, most likely selecting patients that 
suffer most from anatomic and dosimetric changes during treatment. Two studies from 
China investigated the effect of replanning on quality of life [5, 6] (Table 3). In both studies, 
significant lower incidences of side effects were found in the replanning group with respect 
to the no replanning group. Conversely, patients weren’t randomly allocated to the different 
treatment groups, and therefore differences in these specific studies might be explained 
by other factors such as differences in socioeconomic status between the two populations 
[75].
Inaccuracies in the calculation of dosimetric changes
Two factors of inaccuracy in the ART chain that influence the accuracy of the calculation 
of dose on repeat imaging are contouring variability and the dose recalculation procedure 
on (MV)CBCT. Earlier studies showed that the coefficients of variance for contouring OARs 
varied between 12-16% [76] resulting in dose differences of on average 3.5 Gy [77]. Auto-
matic contouring on MVCBCT was found to be comparable to inter-observer uncertainty 
in delineating parotid glands on CT [78]. Morin et al. [79] showed that dose calculation 
on MVCBCT could be performed within a 3% / 3mm accuracy. In kV-CBCT imaging the 
dosimetric error depends on the HU adjustment technique and imaging artefacts. For the 
spinal cord Dmax¬ the error could be >5% [80]. Some dose differences found in this review 
are thus in the same order of magnitude as differences that could be introduced because 
of contouring variability or dose calculation inaccuracy. For instance given a mean dose of 
30 Gy to the PG, a deviation of 3% would result in a deviation of 0.9 Gy. We should therefore 
pay attention to select the most accurate and reproducible segmentation and dose 
calculation procedures to most accurately predict actual given doses.
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Conclusions
 
Despite the relatively large number of studies published so far, the heterogeneity between 
studies prevented unambiguous conclusions on how to select patients for adaptive radio-
therapy in head and neck cancer. Still, a number of potential selection criteria for anatomic 
and dosimetric changes were identified that could be included in well-designed and well-
powered studies on anatomic and dosimetric changes during radiotherapy, including tumour 
location (nasopharyngeal carcinoma), age, body mass index, planned dose to the parotid 
glands, the initial parotid gland volume, and the overlap volume of the parotid glands with 
the target volume. There is a need for larger prospective studies including assessment of 
anatomic and dosimetric changes, and to identify possible relationships between these 
changes and outcome. Moreover, we hope to draw attention to the paucity of good quality 
data on this subject so far, and therewith improve the quality of future research.
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The aim of this study was to develop and validate a method to select head and neck cancer 
patients for adaptive radiotherapy (ART) pre-treatment. Potential pre-treatment selection 
criteria presented in recent literature were included in the analysis.
Materials and methods
Deviations from the planned parotid gland mean dose (PG ΔDmean) were estimated 
for 113 head and neck cancer patients by re-calculating plans on repeat CT scans. 
Uni- and multivariable linear regression analyses were performed to select pre-treatment 
parameters, and ROC curve analysis was used to determine cut off values, for selecting 
patients with a PG dose deviation larger than 3 Gy. The patient selection method was 
validated in a second patient cohort of 43 patients.
Results
After multivariable analysis, the planned PG Dmean remained the only significant parameter 
for PG ΔDmean. A sensitivity of 91% and 80% could be obtained using a threshold of PG 
Dmean of 22.2 Gy, for the development and validation cohorts, respectively. This would 
spare 38% (development cohort) and 24% (validation cohort) of patients from the labour-
intensive ART procedure. 
Conclusions
The presented method to select patients for ART pre-treatment reduces the labour of ART, 
contributing to a more effective allocation of the department resources.  




During the course of head and neck radiotherapy, anatomical changes such as body weight 
and/or tumour volume may result in underdosage or dose inhomogeneity in targets, and 
overdosage in organs at risk (OARs) [1–4]. The largest dose differences between (estimated) 
delivered and planned OAR dose that have been reported are for the parotid glands (PGs). 
However there is a substantial difference in findings between studies, the median of the 
mean dose difference over 25 studies is 1.7 [interquartile range -1.9;10.4] Gy [5]. A larger 
PG dose than planned will increase the risk of xerostomia with subsequent deterioration of 
quality of life [6]. Adaptive radiotherapy (ART) is a strategy used to limit or even decrease the 
dose to the PGs. ART, however, comprises a labour intensive procedure, requires additional 
imaging and does not lead to a clinically relevant benefit for all patients [7]. It would there-
fore be helpful if the patients with expected clinically relevant PG dose deviations could be 
selected prior to radiotherapy. With such a method in place, the selected patients would  
receive an ART procedure to monitor and/or minimize the delivered PG dose. The non- 
selected patients would be spared from this extensive procedure. Many attempts have been 
made to find parameters associated with anatomical and dosimetric changes of PGs [5], but 
there is no general consensus yet on how to select patients for ART to decrease xerostomia.
The aim of this study is therefore to develop a method using pre-treatment parameters 
to predict dose deviations from the planned PG mean dose, which can be used to select 
patients for ART pre-treatment. Two different patient cohorts were used to develop and 




One-hundred and thirteen head and neck cancer patients were enrolled in a previous 
prospective cohort study [8–11]. All patients were treated between 2008 and 2012 
with curative intent. They received primary conventional three-dimensional conformal 
RT (3D-CRT) or intensity-modulated RT (IMRT) up to a dose of 70 Gy in fractions of 2 Gy 
delivered over 6-7 weeks (5 or 6 fractions per week), following ICRU recommendations, 
either alone or in combination with concomitant chemotherapy (chemoradiation) or 
cetuximab (bio-radiation). All patients received a planning computed tomography scan  
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(plan-CT) as well as a post-radiotherapy response CT scan (post-CT) in the treatment 
position, acquired 6 weeks after RT with a slice thickness of 2 mm. This cohort was used to 
develop the patient selection method.
Patient cohort B
Data from 43 patient plans were used to validate the patient selection method. This 
patient group was treated in our department in 2014-2015 with definitive radiotherapy or 
concurrent chemoradiation or bio-radiation using IMRT or Volumetric Modulated Arc Therapy 
(VMAT). The dose prescription was up to 70 Gy in fractions of 2 Gy delivered over 6-7 weeks 
(5 or 6 fractions per week) according to ICRU recommendations. For each patient, the plan 
quality was monitored during treatment by recalculation on weekly repeated CT scans. In 
cases of relevant dose deviation  (repeat-CT with respect to the plan-CT, as judged by the 
treating physician), the treatment plan was adapted. All CT scans were acquired in the 
treatment position, with a slice thickness of 2 mm.
Parotid gland dose deviations
For both cohort A and B, the PGs were delineated on the plan-CT by a dedicated radiation 
therapist, and were warped to the post- and repeat-CTs respectively by deformable image 
registration using Mirada RTx (Mirada Medical Ltd., Oxford, UK). The warped PG contours 
were manually corrected if necessary. For cohort B, 2 ipsilateral PGs were excluded because 
of tumour invasion.
For cohort A, the clinical treatment plan was re-calculated on the post-CT. Subsequently,  
ΔDmean[A] of the PG for each patient was the mean dose of the PG on the post-CT minus 
that of the planned mean dose : ΔDmean[A] = Dmean_post[A] - Dmean_plan[A]. Since 
previous studies showed that the volume of the parotid gland does not significantly change 
after the last fraction of RT [12, 13], we assume that ΔDmean[A] is an accurate estimate of 
the dose deviation between end and start of treatment.
For cohort B, the delivered dose was estimated by dose accumulation of the re-calculated 
dose distribution on weekly repeat-CT scans using deformable image registration 
(Raystation, Raysearch Laboratories AB, Stockholm, Sweden). Next, ΔDmean[B] for the PG 
per patient was calculated by subtracting the planned mean dose from the accumulated 
mean dose : ΔDmean[B] = Dmean_accumulated[B] - Dmean_plan[B]. 
Candidate pre-treatment factors
Previously identified candidate pre-treatment factors [4, 5] that were considered in the 
analysis were: initial weight, BMI, age, chemotherapy (yes/no), surgery (yes/no), T-stage 
(T3+ vs. T3-), N-stage (N2+ vs. N2-), planned dose to the PG (mean dose and V20, V30 and 
V40), initial PG volume, initial gross tumour volume (GTV), tumour location (pharynx vs. 
other) as well as overlap volume (OV) of the PG with the target (high dose) and elective (low 
dose) planning target volume (PTV); OVPG-PTVhigh and OVPG-PTVlow.
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Statistical analysis 
The endpoint for the linear regression analysis was defined as the absolute value of 
ΔDmean, since anatomic changes can result in positive as well as negative dose deviations 
(see Figure 1), which are both of importance for a correct prediction of xerostomia. 
To test whether pre-treatment parameters and endpoints significantly differed between 
cohort A and B, independent samples t-tests, Mann-Whitney U tests and Fisher’s exact tests 
were performed for normally distributed continuous variables, for continuous variables 
with skew distribution and for categorical variables, respectively. A p-value of ≤ 0.05 was 
considered statistically significant.
Univariable and multivariable linear regression analyses were applied to the endpoint 
|ΔDmean[A]| for the contralateral and the ipsilateral parotid gland. For the continuous 
explanatory variables we checked for linear relationship with the endpoint using scatter 
plots of the variables vs. the endpoint, for the final model, we checked normality and 
constant variance of the residuals. Pre-treatment factors with a p-value <0.2 in the 
univariable analyses were included in the multivariable analysis using forward selection 
(Likelihood ratio test, threshold p<0.05). If the pre-treatment factors had a Pearson mutual 
correlation (R) > 0.80, only the factor with the highest correlation to the endpoint was 
included in multivariable analysis. Model performance was scored with the coefficient of 
determination (R2). 
The pre-treatment factor(s) from the final multivariable linear regression model were applied 
to the data to select patients for ART, i.e. patients with a  | PG ΔDmean | > 3 Gy (both ipsi- 
and contralateral PGs included), which was assumed to be the minimum level of clinical 
relevance. Three Gy would result in NTCP differences of 3-10% for xerostomia (depending 
on the applied model and the steepness of the curve for the particular dose value) which 
is assumed as a clinical relevant threshold to select patients for advanced treatments 
[15]. Cut off values were determined by means of receiver operating characteristic (ROC) 
curve analysis, for sensitivities of 70%, 80%, 90% and 100%. The cut off values found were 
applied to dataset B. The sensitivity, specificity, and positive and negative predictive value 
were calculated and used to assess the performance and efficiency of the method.
Statistical analysis was performed using Statistical Program for Social Sciences (SPSS Inc., 
Chicago, IL, USA) and the Statistics Toolbox in Matlab R2014a (MathWorks, Natick, MA, 
USA). 
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FIGURE 1
Distribution of ΔDmean (Gy) against the initial Dmean (Gy) of the contralateral (left) and 
ipsilateral (right) parotid glands.















Fit for the contralateral parot id gland model (R= 0.759)















Fit for the ipsilateral parot id gland model (R = 0.621)
FIGURE 2
Resulting models from the multivariable linear regression analysis (Table 3) for 
ln|ΔDmean| of the contralateral (left) and ipsilateral (right) parotid gland. Predicted values 
(x-axis) are the results from the model, real values (y-axis) are the real data (ln|ΔDmean|).




Patient characteristics of cohort A and B were significantly different regarding gender, 
weight, BMI, T-classification, N-classification, tumour location, use of chemotherapy, Dmean 
of the contra- and ipsilateral PG, GTV volume, and |ΔDmean| of the contralateral PG  
(Table 1). 
The endpoint |ΔDmean| and the pre-treatment factor GTV volume were transformed by 
the natural logarithm to improve linearity and normality. In the univariable analysis, all 
pre-treatment factors were significantly associated (α=0.05) with the endpoint ln|ΔDmean| 
of the parotid glands (Table 2), with the exception of the initial patient weight (for the 
ipsilateral PG), age, surgery and initial PG volume.
The parameters included in the multivariable linear regression for both the contra- and  
ipsilateral PG were BMI (weight excluded due to the mutual correlation), chemotherapy, 
T-stage, N-stage, PG Dmean (PG V20, V30, V40 excluded due to the mutual correlation), 
tumour location, ln (GTV volume) and overlap PG-PTV56 (overlap PG-PTV70 excluded due to 
mutual correlation). From the multivariable linear regression analysis, the planned mean 
dose to the PG was the only significant factor (Table 3). The coefficient of determination for 
the final model was R2 = 0.59 (contralateral PG) and R2 = 0.39 (ipsilateral PG) (Figure2).
For 20% of the parotids in cohort A, |ΔDmean| of the parotid gland was higher than 3 Gy 
(Figure 3, Table 4). The results of the ROC curve analysis for sensitivities of 100, 91, 80 and 
71% are shown in Table 4. For a sensitivity of 91%, the specificity was 45%, and 62% of the 
parotids would be selected for the ART procedure. The positive predictive value was 29%, 
meaning that 29% of the parotids that were selected for ART with our method were correctly 
classified. The negative predicted value was 95%.
The cut off values of PG Dmean (Gy) found for cohort A were applied to cohort B to validate 
the selection method, resulting in the performance measures for cohort B (Figure 3, Table 4). 
For 18% of the parotids in cohort B, |ΔDmean| of the parotid gland was higher than 3 
Gy (Figure 3, Table 4). Applying the cut off value for PG Dmean of 22.2 Gy, the sensitivity 
was 80% and 76% of the parotids would be selected for the ART procedure (Table 4). The 
positive predictive value was 19% and the negative predicted value 81%.
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TABLE 1 
 
Patient characteristics of cohort A and B (percentages for categorical variables, means 
(sd) for normally distributed continuous variables and medians [inter quartile range] for 
continuous variables with skew distributions). PG= parotid gland, GTV= gross tumour 
volume, ipsi= ipsilateral, contra= contralateral. P-values resulting from independent samples 
t- test ((1), normally distributed continuous variables), Mann-Whitney U test ((2), continuous 
variables with skew distributions) and Fisher’s exact test ((3), categorical variables). 
Statistically significant values presented in bold.
Cohort A Cohort B p-value
Gender
   Male





















   T1-T2







   N0-N1






Tumour location/ primary site
   Pharynx







   yes














Initial volume PGcontra (cm
3)
Initial volume PGipsi (cm
3)


























* difference in volume between start and final week of radiotherapy
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Cohort A Cohort B 
Cut off value 
22.2 Gy 
Cut off value 
22.2 Gy 
FIGURE 3
Deviation from the planned parotid gland mean dose (|ΔDmean|) 
vs. the planned parotid gland mean dose. Selection of patients for 
|ΔDmean| > 3 Gy with 91% and 80% sensitivity could be performed 
by using a threshold of Dmean = 22.2 Gy, for cohort A and B, 
respectively (for more information refer to Table 4).
Cohort A Cohort B 
Cut off value 
22.2 Gy 
Cut off value 
22.2 Gy 
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TABLE 2 
 
Univariable linear regression for the endpoint ln|ΔDmean| of the contralateral (contra) 
and ipsilateral (ipsi) parotid glands. Statistically significant values presented in bold.
Pre-treatment factor Regression coefficient Standard error p-value Pearson R
Contra Ipsi Contra Ipsi Contra Ipsi Contra Ipsi
BMI -0.136 -0.172 0.041 0.043 0.0015 0.0001 -0.317 -0.380
Weight -0.030 0.558 0.011 0.465 0.0136 0.2336 -0.240 0.121
Age -0.018 -0.031 0.017 0.018 0.3053 0.0959 -0.096 -0.157
Chemotherapy 1.604 1.397 0.441 0.463 0.0004 0.0030 0.323 0.275
Surgery -0.234 0.670 0.615 0.679 0.7044 0.3257 -0.036 0.094
T-stage 1.426 1.200 0.371 0.392 0.0002 0.0027 0.340 0.279
N-stage 1.685 1.678 0.356 0.371 <0.0001 <0.0001 0.407 0.395
PG Dmean 0.107 0.063 0.009 0.007 <0.0001 <0.0001 0.759 0.621
PG V20 0.029 0.038 0.004 0.004 <0.0001 <0.0001 0.531 0.691
PG V30 0.037 0.039 0.004 0.004 <0.0001 <0.0001 0.638 0.644
PG V40 0.041 0.037 0.007 0.005 <0.0001 <0.0001 0.483 0.569
PG volume -0.017 -0.002 0.020 0.019 0.3899 0.9331 -0.080 -0.008
Ln(GTV volume) 0.781 0.698 0.121 0.134 <0.0001 <0.0001 0.529 0.453
Tumour location 1.720 1.325 0.362 0.391 <0.0001 0.0010 0.408 0.306
Overlap PG -PTV70 0.502 0.120 0.205 2.154 0.0159 0.0335 0.226 0.203
Overlap PG -PTV56 0.270 0.160 0.062 0.033 <0.0001 <0.0001 0.384 0.419
TABLE 3 
 
Results of the multivariable linear regression analysis for the endpoint 
ln|ΔDmean| of the contralateral (contra) and ipsilateral (ipsi) parotid gland.
Regression coefficient Standard error p-value
Contra Ipsi Contra Ipsi Contra Ipsi
Intercept -2.78 -2.22 0.231 0.264 <0.001 <0.001
PG Dmean 0.107 0.063 0.009 0.007 <0.001 <0.001




Performance of the classification of patients for |ΔDmean| of the parotid 
glands > 3 Gy by using the planned mean dose of the parotid glands (PG 
Dmean). n.a.= not applicable.
Cut off value PG Dmean (Gy) 0  3.6 22.2 24.7 27.0
Cohort A (n=226)
Sensitivity (%) 100 100 91 80 71
Specificity (%) 0 33 45 50 60
% selected for ART 100 74 62 56 46
Positive predictive value (%) 20 27 29 29 30
Negative predictive value (%) n.a. 100 95 91 89
Cohort B (n=82)
Sensitivity (%) 100 100 80 60 40
Specificity (%) 0 0 25 38 46
% selected for ART 100 100 76 62 51
Positive predictive value (%) 18 18 19 17 14
Negative predictive value (%) n.a. n.a. 81 81 78
FIGURE 4
Parotid gland volume change 
against the initial Dmean 
(Gy) of the contralateral and 
ipsilateral parotid glands 
(cohort A). Line represents the 
linear fit of the parotid mean 
dose vs. the parotid volume 
change for the ipsilateral 
parotid glands with initial 
parotid mean dose level < 60 
Gy (R2=0,274).
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Discussion 
 
In univariable analysis, many of the pre-treatment parameters were significantly associated 
with the change in mean dose to the parotid gland (Table 2). Still, Pearson correlation 
with the endpoint was low for most of the parameters. The only parameter that remained 
significant in a multivariable analysis was the planned mean dose to the parotid gland. By 
selecting only patients with a planned PG mean dose ≥ 22.2 Gy for an ART procedure, 87% 
of patients in the validation cohort who needed replanning (i.e. having PG |ΔDmean| > 3 
Gy) were selected (Table 4). This would spare 24% of patients in the validation cohort from 
the ART procedure, which would contribute to a more effective allocation of the department 
resources.
In our previous review study [5] we found a number of candidate pre-treatment parameters 
to identify patients that might benefit from ART. In seven studies, the PG mean dose was 
significantly associated with PG volume loss [12, 16–21], suggesting its potential as a 
predictor for dose changes. In the multivariable analysis of the current study, the direct 
relationship between the planned PG mean dose and deviations from the planned PG mean 
dose was confirmed (R2=0.59 and 0.39 for contra- and ipsilateral PG, respectively). The BMI 
[19] and initial parotid volume [16] were previously significantly associated with PG volume 
loss in multivariable analysis. In the current study these factors were only significantly 
correlated to PG volume loss in univariable analysis (Table 2), but not in multivariable 
analysis.
The inferior performance of the linear model for the ipsilateral PG compared to the contra-
lateral PG could be explained by the fact that the ipsilateral PGs are often encompassed 
by an (elective) target volume. Consequently, the ipsilateral PGs are more often receiving a 
high, homogenous dose, and are located further away from high dose gradients. Anatomical 
changes will therefore have little or no dosimetric impact for the ipsila teral PGs receiving 
high doses (>~50 Gy). Furthermore, we found that PG volume loss was linearly associated 
with the PG mean dose up to a level of ~60 Gy, but for PG doses >60 Gy, little or no PG 
volume loss (i.e. anatomical changes) occurred (Figure 4).  
Brown et al. [4] also attempted to predict the need for ART in head and neck cancer 
patients. The authors concluded from their multivariable analysis that oropharyngeal and 
nasopharyngeal patients with N2-3 disease, an initial weight > 100 kg and larger initial 
nodal sizes have a probability ≥ 80% of requiring replanning. In our multivariable analysis, 
only the mean dose to the PG persisted. While Brown et al. did not include this factor in 
their analysis, in our data the PG mean dose was significantly associated with N2-3 disease 
(R=0.51) and larger initial nodal sizes (R=0.43). Furthermore, the difference in findings 
between our study and those reported by Brown et al. can be explained by a number of 
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reasons.  First, Brown et al. used a different endpoint, i.e. ‘the need for replan’, which was 
defined by the treating radiation oncologist. As the authors stated in their discussion, the 
need for replan was mostly defined by the dose to the optic structures and brachial plexus. 
In our study, the need for replan was determined by the dose to the parotid gland.  Secondly, 
our study cohort contained fewer patients with oro- and nasopharyngeal cancer. Thirdly, 
our patients with pharyngeal cancer had lower initial weights, not exceeding the 100 kg 
threshold described by Brown et al.. It will be necessary to repeat the multivariable analyses 
in sufficiently large, properly selected patient cohorts, in order to untangle the confounding 
factors.
In the study by Brown et al. [4], only 5 of 110 patients (4.5%) were selected for replanning. 
In our study, 18-20% of the patients were selected for replanning if their difference in mean 
dose to the PG  was larger than 3 Gy. The question arises whether the arbitrary threshold 
of 3 Gy is the most clinically relevant threshold. In the linear range of the mean dose NTCP 
model (from a mean dose of ~25 up to 55 Gy) [14], a difference of 1 Gy in mean dose 
to the PG corresponds to a difference of about 3% in NTCP. For dose values <25 or >55 
Gy however, a difference of 1 Gy in mean dose to the PG corresponds to a difference of 
about 1% in NTCP. Still, it is hard to prove that a dose increase of 3 Gy will result in more 
complications. Some authors [22, 23] compared the intensity of side effects and global 
quality of life of a group of patients selected for replanning with those without replanning. 
They found significantly fewer side effects and improved quality of life for the replanned 
group. However, it should be noted that in these studies patients were not randomly 
allocated to the different strategies. Therefore the differences found in these studies can 
also be explained by other factors, such as differences in socioeconomic status between the 
two populations [24]. 
The strengths of our study are the relatively large number of patients included and the use 
of two independent patient groups for development and validation of the selection method. 
We were therefore able to perform multivariable analysis to select the most important pre- 
treatment parameter(s) related to the endpoint, and eventually to validate this approach in 
an independent subsequent patient cohort.
A limitation of our study is the absence of imaging during the course of RT for cohort A. 
Therefore, the approximated delivered dose to the PG for cohort A may be overestimated. 
However, we expect the post-CT scan acquired six weeks after RT to be a valid 
approximation for the anatomy of the parotid gland, since previous research showed no 
significant change in volume of the parotid glands 6-8 weeks after treatment in relation 
to the end of treatment [12, 13]. We choose to calculate ΔDmean[B] using all available 
imaging during the course of radiotherapy, to obtain the best approximation of the actual 
given dose. This approach is expected to result in lower values of ΔDmean than the 
approach taken in cohort A. The fact that resulting ΔDmean values for cohort B are even 
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higher than the values in cohort A can be explained by the differences between the cohorts, 
i.e. tumour location and initial GTV volume (cohort B having a larger amount of pharynx 
patients, and a larger initial GTV volume).
The focus of this study was the dose deviations of the PG, for two reasons. The first is that 
previous studies have shown that this organ receives the largest dose deviations [1-3]. The 
second is because the dose to the PG is related to one of the most important long term side 
effects of head and neck radiotherapy. At present, we are conducting studies investigating 
the consequences of dose inhomogeneities of target volumes, and potential overdosage 
of other organs at risk due to anatomical changes. The same method as described in this 
study could be used to study pre-treatment parameters associated with dose changes and 
to classify patients suitable for ART. 
Absolute changes from the planned PG mean dose were considered in this study, i.e. 
positive as well as negative dose changes. If the dose change to the PG is positive, a 
plan adaptation is needed to prevent a higher risk of xerostomia than predicted at the 
planning stage. Although negative dose changes result in a lower risk of xerostomia, it is 
also important to monitor since the original treatment plan might become compromised, 
requiring further optimization of the target volume or other organs at risk.
The patient characteristics of patient cohort A and B showed several significant differences, 
with regard to tumour location, tumour and node classification, chemotherapy, GTV 
volume and planned PG mean dose and |ΔDmean| of the contralateral PG (Table 1). The 
performance of the classification of patients for PG |ΔDmean| > 3 Gy was moderate for 
cohort B (Table 4). With the low threshold of 3.6 Gy, all patients were selected for ART (the 
minimum PG mean dose was 5.4 Gy). With high thresholds however (24.7 and 27.0 Gy), 
the sensitivity was only 60% and 40% respectively, which would generally not be accepted 
in clinic. Nevertheless, the threshold of 22.2 Gy is applicable to both cohort A and B with 
similar sensitivity (91% and 80%, respectively). Therefore a threshold for the mean dose 
to the parotid gland of 22.2 Gy seems optimal for the selection of head and neck cancer 
patients for ART, with reasonable overall performance (Table 4). The sensitivity level 
accepted is obviously discussable, and depends on the desired level of accuracy and the 
availability of resources for ART.The somewhat disappointing performance of the selection 
tool in general pleads for future studies using more specific patient populations, i.e. with 
focus on a specific tumour location. 
In summary, we have presented a method to select patients for ART pre-treatment by using 
the planned mean dose to the parotid gland. Additional studies focusing on dosimetric 
changes to target volumes and organs at risk in large specific patient cohorts could help to 
further specify appropriate parameters to select patients for ART.
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120   CHAPTER 7 - Summarizing discussion and future perspectives
The overall purpose of this thesis was to quantify the effect of two of the major factors of 
uncertainty in current radiotherapy treatment with regard to head and neck organs at risk 
(OARs): delineation variability and anatomical variability during the course of treatment. 
Reduction of these uncertainties is of major importance since advanced treatment 
techniques, such as proton therapy, can be delivered with high conformity and therefore 
require an adequate definition of structures before and during the course of therapy. 
Variability in delineation
Variation in delineation of anatomical structures in the head and neck region involved in 
swallowing was demonstrated by major differences between delineation guidelines for 
OARs in the head and neck region (Chapter 2). The 3-dimensional dose distributions to 
some of these swallowing structures can be used as input parameters in Normal Tissue 
Complication Probability (NTCP) models in order to predict the probability of radiation-
induced swallowing dysfunction in individual patients. In this chapter, the variability in 
NTCP values due to the variation between guidelines and subsequent variation in dose 
parameters was studied. In some cases, the variation in dose parameters resulted in 
relatively large absolute differences in anticipated NTCP-values (i.e. >10%). These findings 
emphasize the importance of using the same delineation guidelines as those that were 
used to develop and validate the NTCP-models. For a broad introduction of NTCP-models 
into routine clinical practice, generally accepted consensus guidelines and corresponding 
NTCP-models are required. 
In Chapter 3, interobserver variability within specific delineation guidelines was quantified 
for a set of head and neck OARs, including the spinal cord, parotid and submandibular 
glands, thyroid cartilage and glottic larynx by different measures of variability and 3D 
analysis over sub-regions. The results from this analysis revealed the regions with the 
largest variability for each OAR. Overall, the largest variability was observed for the cranial 
region of the OARs. A number of reasons for this variability could be identified, including 
indistinctness of the delineation guidelines, the lower image resolution in the cranial-caudal 
direction (determined by the slice thickness), and poor difference in contrast with adjacent 
tissues. Apart from improving the delineation guidelines, the importance of delineation 
meetings and training was stressed to optimize compliance to the guidelines.  
The main difficulty in the interpretation of results in our but also in other studies that 
investigated interobserver variability, is the lack of ‘gold standard’ contours. Ideally, surgical 
specimens could be used to verify the accuracy of delineations as has been done for 
prostate cancer delineation [1], but obviously this is not an option for normal tissues in the 
head and neck. 
Therefore, the accuracy of OAR delineation is generally derived from interobserver variability 
relative to other observers, measuring the variation amongst the different contours 
[2–4]. Commonly used measures include the analysis of volumes [5, 6], the conformity / 
conformality / (dis)concordance index or Jaccard coefficient [2, 7–10], the Dice Similarity 
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Coefficient (DSC) [5], and the Hausdorff distance [6]. In addition, the distance of each 
contour to a reference contour is commonly used, giving a common frame of reference to 
determine the statistical variation of each of the contouring metrics. The choice of this ‘gold 
standard’ reference contour varies in the literature from a mathematical average contour 
[11–13], a STAPLE (simultaneous truth and performance level estimation) consensus 
contour [14], a radiologist- or experienced oncologist-defined contour [15] or a consensus 
contour that is decided upon by a panel of experts [16, 17]. 
There is no consensus on a general set of tools to use to describe interobserver variability in 
contouring. A combination of measures of volume, position and 3D distance, independent 
of the number of observers, would provide a comprehensive overview of interobserver 
variability. Objective measures on interobserver variability are useful for guideline 
development, and could serve as a benchmark against automated contouring procedures. 
Valentini et al. [18] presented a set of recommendations with regard to the ontology 
definition, performance evaluation tools and benchmark evaluation methods. These authors 
also advice to describe the existing contouring variability from different points of view, using 
a combination of multiple different tools.
Based on the results described in Chapter 2 and 3, and in collaboration with a number 
of international experts in the field of head and neck radiation oncology, we proposed 
CT-based consensus delineation guidelines for head and neck OARs in Chapter 4. These 
consensus guidelines have been endorsed by all major cooperative head and neck cancer 
research groups worldwide, including DAHANCA, EORTC Head and Neck Cancer Group, 
EORTC Radiation Oncology Group, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology 
and TROG. Furthermore, the guidelines have been integrated in ESTRO teaching courses. 
In addition, the Dutch Platform for Head and Neck Radiotherapy (LPRHHT) decided to use 
these guidelines in the Netherlands which was further supported by the organization of a 
workshop for head and neck radiation oncologists in the Netherlands. 
At present, over 900 head and neck cancer patients that have been included in the Head 
and Neck Standardized Follow-up Program (SFP) of the department of radiation oncology 
of the UMCG from 2007 on, are re-delineated according to the new consensus guidelines 
to develop a complete set of new NTCP models for head and neck cancer patients (Dutch 
Cancer Society Project: CITOR).
After the introduction of the consensus guidelines, we demonstrated that the interobserver 
variability was reduced for most OARs investigated [19]. The average 3D variation in 
distance for 6 observers before and after the introduction of the guidelines was 3.7 mm 
and 2.4 mm (1 SD), respectively. Out of 20 OARs, 16 OARs showed reduced 3D variation 
(reduction range  0.1-10.8 mm) using the consensus guidelines. The largest reduction of 
4.3 mm was seen for the oral cavity, from 6.4 mm to 2.1 mm (Figure 1).
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FIGURE 1
In the consensus guidelines, the use of MRI in addition to CT is advised in case of limited 
discrimination between the OAR and its surrounding tissue, in particular for the brainstem, 
optic chiasm and optic nerve. The addition of MRI to CT has demonstrated to improve 
delineation accuracy for GTVs in the head and neck [20, 21]. Also for the parotid glands, 
MRI would facilitate the delineation of the deep lobe, and allow for an easier distinction 
between the vascular and the glandular structures of the parotid glands [8]. 
With the increasing use of MR (and PET) imaging in radiotherapy treatment planning, it is of 
importance to follow established, consistent image registration procedures. Furthermore, 
improved geometric accuracy of MRI is required. Phantoms and analysis software have 
been developed to characterize distortions in MRI scans [22, 23]. Moreover, commercial 
solutions have become available to measure and correct for geometric distortion.
Contours of the oral cavity delineated on CT (left) without (above) and with (below) 
consensus guidelines. Right side shows 3D variation (1SD).
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As stated in Chapter 4, we anticipate that the guidelines will be updated in the near future, 
incorporating new relevant anatomical and functional information, e.g. using (f)MRI and 
incorporating (subregions of) OARs that are most relevant for side effects. This is illustrated 
by a recent publication on the parotid gland, demonstrating that the radiation dose to the 
region containing the stem and progenitor cells correlated better with post-treatment saliva 
production than the radiation dose to the whole gland [24].
We expect that the updated guidelines will contribute to a further improvement of NTCP 
modelling (Figure 2). 
(Updated and 














Delineation guidelines (I) and accounting for geometric changes (II) will lead to most 
accurate and consistent DVH parameters (III). This provides the possibility to develop 
improved NTCP models (IV), which will in turn define the updated set of delineation 
guidelines (I).
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Anatomical variation during the treatment
As stated in the introduction, the number of publications on anatomic and dosimetric 
changes increased rapidly in the last decade. Therefore, we systematically reviewed the 
literature to obtain better insight in anatomic and dosimetric changes of head and neck 
OARs during radiotherapy, including the implications of these changes for the rate and 
severity of complications and quality of life (Chapter 5). 
The results of this review revealed that the parotid gland was the most studied OAR. The 
parotid glands normally shrink to 60-80% of their initial volume at the end of treatment. 
Various results regarding dosimetric impact of this shrinkage were reported in the different 
studies, with a median value of the mean parotid gland dose difference over 25 studies of 
1.7 [-1.9-10.4] Gy.
The reason that the parotid glands have been subject to so many studies is twofold. Firstly, 
the dose to the parotid glands is related to the most frequently reported late radiation 
induced side effect [24–26], i.e. salivary dysfunction and subsequent xerostomia. Secondly, 
the parotid glands show large anatomic changes over time during the course of treatment 
(Chapter 5).
The reason of the large variety in the results of the dosimetric effects can be explained by 
differences in patient population (e.g., nasopharynx vs. other locations) and differences 
in treatment techniques (e.g., different margins, OAR-based treatment plan optimization 
versus conventional treatment planning, etcetera). Another limitation is that most studies 
only consisted of limited patient populations.
Selection of a subgroup of patients for an adaptive radiotherapy approach would enable 
adaptive radiotherapy for more radiotherapy departments, since the procedure is still highly 
labour intensive and thus relatively expensive. Therefore, selection of patients that will 
benefit most from this approach may be more cost effective and may improve a more widely 
clinical introduction.
Potential selection criteria for adaptive radiotherapy can be divided in pre-treatment and 
per-treatment selection factors. We identified a number of potential pre-treatment factors 
(Chapter 5) including primary tumour site, age, body mass index, planned dose to the 
parotid glands, the initial parotid gland volume, and the amount of overlap volume of the 
parotid glands with the clinical target volumes around the lymph node metastases. Potential 
per-treatment selection factors were weight loss, reduction of lateral neck diameter, parotid 
gland volume decrease, parotid gland density decrease, distances between parotid gland 
centres of mass and GTV volume decrease. 
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An important limitation of the studies performed so far is that many of these consisted 
of relatively small patient populations and were mainly based on univariable analyses. 
To identify prognostic factors for volume changes that eventually result in relevant dose 
distortions, prospective studies are desperately needed including assessment of anatomic 
and dosimetric changes as well as multivariable analysis. Since only limited data on the 
effect of dosimetric changes on the risk of radiation-induced side effects and/or on quality 
of life were found (Chapter 5), these aspects should be taken into account as well in future 
studies to determine the ultimate clinical impact of adaptive radiotherapy.







































NTCP model Xerostomia 6 months after radiotherapy according to Beetz et al. [25].  
A mean dose difference of 10 Gy to the contralateral parotid gland results in a different 
NTCP difference, depending on the initial dose level.
126   CHAPTER 7 - Summarizing discussion and future perspectives
We conducted a retrospective analysis on prospectively derived data to develop and validate 
a method to select head and neck cancer patients for adaptive radiotherapy in Chapter 6. 
Two different patient cohorts were available for the development and validation of a 
multivariable prediction model to identify patients with dose deviations to the parotid gland 
of more than 3 Gy (Δdose3Gy). The only parameter in the multivariable analysis with a 
significant association with Δdose3Gy was the mean dose to the parotid gland. Using this 
single parameter, a sensitivity of 80% could be obtained when a threshold of parotid gland 
Dmean of 22.2 Gy was used. This would spare 24% of the patients from the labour-intensive 
adaptive radiotherapy procedure.
The question arises whether using a threshold for Δdose to the parotid gland of 3 Gy for 
patient selection results in a clinically relevant reduction of side effects in terms of the 
risk of xerostomia. For some patients, a Δdose of more than 3 Gy translates to a clinically 
relevant ΔNTCP of more than 10%, while in other patients, the same Δdose is not expected 
to translate in a clinically relevant NTCP reduction (Figure 3). The effect of Δdose on the 
NTCP depends on the baseline dose level and the NTCP model applied [25, 26]. When 
proper externally validated NTCP models would be available, the expected ΔNTCP could 
become part of the selection process for ART, analogous to the selection procedure for 
proton therapy [27].
Future perspectives
The work presented in this thesis focussed on delineation variability for manual contouring 
and anatomical variability during the course of treatment. Four different other aspects 
may further reduce uncertainty with regard to head and neck OARs definition and/or 
administered dose.
First of all, to facilitate uniform contouring procedures, dedicated delineation software 
may increase consistency among radiation oncologist world-wide. Fortunately, (semi)
automatic delineation software for OARs is increasingly applied in routine clinical practice. 
This software is designed to integrate different imaging modalities and offers optimized 
contouring tools, such as the use of threshold contouring and the ability to delineate OARs 
in every desired image orientation. Software dedicated to contouring often offers the ability 
for (semi-) automatic and/or atlas-based delineation. Application of (semi-) automatic 
delineation has proven its efficacy for certain OARs [28–35], but clinicians should still 
carefully review and if necessary adjust every automatically generated contour. At present, 
efforts are being made to automate the quality assurance of automatic delineation, by 
using a database of validated contours and review every new contour by comparison with 
the database contours [36, 37]. Such a system would also be helpful for training purposes. 
For consistency in retrospective analysis and multicentre studies, it is of importance to use 
similar validated atlases and deformable image registration algorithms for every patient. 
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Second, by the increasing use of improved fixation and online image guidance, setup 
variations have been reduced significantly. Online verification using conebeam CT increased 
the set-up accuracy, allowing a margin reduction between CTV and PTV of 2-3 mm [38].  
It should be emphasized that position verification as such is not able to compensate for 
anatomical changes. An adaptive procedure is necessary in which the treatment plan is 
re-optimized for the altered anatomy. 
A third aspect that will reduce uncertainty in the definition and administered dose to head 
and neck OARs is the future application of offline or online adaptive (proton) therapy. 
Different adaptive radiotherapy strategies including one or two plan adaptations during the 
treatment have been proposed to be effective to reduce dose to OARs [39–42]. Potentially, 
adaptive radiotherapy would also enable margin reduction and therewith further reduce the 
dose to OARs.
We believe that adaptive radiotherapy is an essential tool for a successful introduction of 
proton therapy,  where anatomic changes may have a significantly larger impact on the 
delivered dose distribution than in photon therapy [43]. 
Important requirements for adaptive therapy are in-room and/or out-room (CB)CT and/
or MR imaging in combination with advanced patient transport systems from CT to gantry, 
QA controlled deformable image registration for contour propagation and dose warping, 
fast treatment planning and plan QA, and integration of hard- and software of all of the 
aforementioned components. We are currently putting efforts into realizing these different 
aspects for our proton therapy facility (the UMC Groningen Particle Therapy Center (GPTC)). 
Fortunately, more and more vendors provide software for workflow automation of adaptive 
radiotherapy. On line 3D image guidance is relatively new in proton therapy as the first cone 
beam-CT-scan systems are only recently installed.
From a clinical perspective, the exact role of adaptive radiotherapy remains to be defined. 
Recent studies [44] showed encouraging post-treatment functional recovery with regard 
to late toxicity (12 months) for 22 patients treated with adaptive radiotherapy. Other 
studies [45, 46] reported significantly lower incidences of side effects in the patient group 
treated with adaptive radiotherapy with respect to those observed in the group treated 
without adaptive radiotherapy. Patients were, however, not randomly selected for the 
adaptive radiotherapy scheme, and therefore differences between patient groups might 
be explained by other factors such as differences in socioeconomic status between the 
two populations. The ESTRO annual meeting of 2016 entitled a proffered paper session 
‘Adaptive radiotherapy: Hype or Hope?’ to update the community with recent findings on 
this subject (including our findings as presented in Chapter 6 [47]). This underlines that the 
clinical benefit of adaptive radiotherapy is still under discussion in the radiation oncology 
community. We need to wait for more clinical results on adaptive radiotherapy to get more 
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knowledge about the effect of adaptive radiotherapy on tumour control and the occurrence 
of complications.
A fourth and last aspect that will aid to reduce (uncertainty of) dose to OARs is robust 
treatment planning. The main objective of robust treatment planning is to produce 
treatment plans that are robust with regard to 3D dose distributions to the different sources 
of uncertainty. Robust treatment planning originated in proton therapy to account for 
different sources of range uncertainty [48], but also finds its application in photon therapy 
[49]. Including robustness into a multicriteria optimisation framework would provide the 
possibility to balance robustness and conformity [48]. Current implementations of robust 
treatment planning simulate geometric changes by applying setup errors [49] using 
scenario-based treatment plan optimization [50]. The latter accounts for different scenarios 
of geometric uncertainty, and re-optimizes the treatment plan to cover the plan criteria 
in all of the proposed scenarios. Apparently, uncertainties will be more complex and not 
only depend on the setup error, but also on the anatomical location, IGRT workflow, type 
of geometric changes and use of adaptive planning. Further research including analysis of 
repeated imaging over the course of treatment will be necessary for each specific indication.
The choice of position verification procedures, adaptive radiotherapy schedules and levels 
of robustness of the treatment plan involves a hierarchy of decisions, each of which balance  
complexity versus flexibility and conformity versus robustness.
Apart from reducing factors of uncertainty in current radiotherapy treatment, it is also 
important to improve the accuracy of endpoints to develop reliable NTCP models. In case 
of patient or physician rated endpoints, a consistent way of scoring and grading is required, 
which requires adequate instructions. Objectification of endpoints would also contribute in 
this perspective. For quantification of xerostomia and sticky saliva by image biomarkers, 
the first studies showed promising results [51]. Changes of biomarkers over time, such 
as reduction of the parotid gland volume, have also shown to be related to the severity of 
late xerostomia [52]. So information concerning changes of OARs during RT are not only 
important because of their consequential dosimetric changes, it could also help us to 
identify patients that are at excess risk to develop complications. 
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Radiotherapie is een belangrijk onderdeel van de behandeling van patiënten met hoofd-
halskanker [1]. Tumor controle en overleving zijn de laatste jaren sterk verbeterd door 
de combinatie van radiotherapie met chemotherapie of biologische geneesmiddelen 
zoals cetuximab [2, 3]. Daarnaast neemt de incidentie van HPV (humaan papillomavirus) 
gerelateerde orofarynx kanker toe [4–6]. Patiënten met HPV-positieve tumoren die 
behandeld worden met radiotherapie, eventueel aangevuld met chemotherapie, vertonen 
een significant betere prognose dan patiënten met HPV-negatieve tumoren [7, 8]. 
De verbeterde overleving zoals hierboven beschreven zorgt ervoor dat een steeds grotere 
groep patiënten leeft met bijwerkingen als gevolg van de radiotherapie. Xerostomie (het 
hebben van een droge mond) is de meest gerapporteerde ernstige en vaak voorkomende 
bijwerking, welke nog lang na de radiotherapie kan aanhouden [9–11]. Ook slikklachten 
worden vaak gerapporteerd, en hebben net als xerostomie een groot effect op de kwaliteit 
van leven [11].
Een belangrijke verbetering van de radiotherapie techniek was de invoering van 
intensiteitsgemoduleerde radiotherapie (IMRT), waardoor de stralingsdosis op gezonde 
amenvatting 
Geometrische variaties 
van risico-organen in 
hoofd-hals radiotherapie
Kan de bestraling van hoofd-halskanker 
patiënten consistenter en efficiënter?
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weefsels kon worden verminderd. Het aantal gevallen van xerostomie is hierdoor significant 
afgenomen (12–14). Zes maanden na afloop van de behandeling, lijdt toch nog altijd meer 
dan de helft van de hoofd-halskanker patiënten aan xerostomie [15]. 
Dosis op de speekselklieren, en met name op de glandula parotis, wordt vaak geassocieerd 
met het optreden van klachten van xerostomie [15–17]. Voor slikklachten is de dosis op de 
slikstructuren van belang [15–18]. Voorspellende modellen kunnen worden gebruikt voor 
het berekenen van de kans op het optreden van een bepaalde complicatie, de zogeheten 
‘normal tissue complication probability (NTCP)’ [19]. Dit zijn bijvoorbeeld multivariabele 
logistische regressie modellen met als input klinische en dosimetrische factoren (20).
Een NTCP model kan gebruikt worden voor het optimaliseren van een bestralingsplan, 
door de dosis op de risico-organen - en daarmee het risico op complicaties - te verkleinen, 
terwijl de kans op tumorcontrole gelijk gehouden wordt. Een NTCP model kan ook gebruikt 
worden voor het selecteren van patiënten voor een geavanceerde bestralingstechniek, zoals 
protonen therapie [21].
Variaties in de intekening van risico-organen en anatomische variaties tijdens de bestraling 
(variaties in vorm en positie van zowel doelgebieden als gezonde weefsels) zijn belangrijke 
bronnen van onzekerheid in de bepaling van correcte dosis parameters [22]. Het verkleinen 
van deze variaties - en dus vergroten van de nauwkeurigheid van dosis parameters - is 
van belang voor een zo nauwkeurig en generiek mogelijke ontwikkeling en toepassing van 
NTCP modellen. In dit proefschrift zijn intekenvariatie en anatomische variaties tijdens de 
bestraling in kaart gebracht. Daarnaast is het effect op de dosisverdeling onderzocht en zijn 
aanbevelingen gedaan voor het verkleinen van deze variaties.
Intekenvariatie
Intekenvariatie is in de orde van 3-8mm, en kan resulteren in suboptimale 
bestralingsplannen waarbij deze systematische fouten kunnen leiden tot overdosering van 
risico-organen en onderschatting van de kans op complicaties [23–25].
De oorzaak van intekenvariatie kan liggen in matige beeldkwaliteit, beperkingen van 
de intekentool en/of interpretatieverschil, veroorzaakt door verschillen in opleiding 
en training en/of verschillen in gebruikte richtlijnen. De beeldkwaliteit (CT en MRI) 
verbetert, intekentools worden geavanceerder en er worden al veel intekenbesprekingen 
georganiseerd. Het invoeren van consensus richtlijnen draagt bij aan het verder reduceren 
van intekenvariatie [26]. Voor het intekenen van doelgebieden zijn eerder al internationale 
consensus richtlijnen gedefinieerd [27, 28], eenduidige richtlijnen voor het intekenen van 
de risico-organen bestonden tot nu toe niet. 
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In hoofdstuk 2 van dit proefschrift zijn de verschillen tussen bestaande intekenrichtlijnen 
van slikstructuren onderzocht, waarbij het effect op dosis parameters en daaruit volgende 
NTCP waarden is vastgesteld. Voor een aantal patiënten zou een NTCP waarde meer dan 
10% kunnen afwijken, wanneer intekenrichtlijnen worden gebruikt die verschillen van 
die van het NTCP model. Het is daarom van groot belang om te komen tot consensus 
intekenrichtlijnen, en bijbehorende NTCP modellen.
In hoofdstuk 3 van dit proefschrift is de intekenvariatie binnen een richtlijn in kaart 
gebracht voor o.a. de speekselklieren, waarbij verschillen per subregio per orgaan zijn 
geanalyseerd. De craniale regio’s vertoonden de grootste variatie (>3mm). Mogelijke 
oorzaken voor de gevonden variatie zijn onduidelijkheden in de richtlijn, de lagere 
CT-resolutie in de cranio-caudale richting (bepaald door de dikte van de CT coupes) en  
matig onderscheidend vermogen van het orgaan met het omliggende weefsel. De resultaten 
van dit hoofdstuk zijn waardevol voor het verbeteren van de intekenrichtlijnen, evenals voor 
het beoordelen van de kwaliteit van automatische intekentools.
De resultaten van hoofdstuk 2 en 3 hebben geleid tot een conceptversie consensus 
intekenrichtlijnen. Dit concept is besproken met internationale experts in de hoofd-hals 
radiotherapie en met vertegenwoordigers van verschillende internationale radiotherapie 
organisaties, wat heeft geleid tot de definitieve consensus richtlijnen zoals beschreven 
in hoofdstuk 4. Deze intekenrichtlijnen zijn geaccordeerd door de internationale hoofd-
halskanker organisaties DAHANCA, EORTC Head and Neck Cancer en Radiation Oncology 
Group, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology en TROG. In een eerste studie 
is al aangetoond dat de invoering van de consensus intekenrichtlijnen leidt tot een lagere 
interobserver variatie voor een groot aantal van de ingetekende structuren [29]. De 
consensus intekenrichtlijnen zijn geïntegreerd in ESTRO teaching courses en in Nederland 
is onlangs een intekenworkshop georganiseerd door het Landelijk Platform Radiotherapie 
Hoofd-Hals Tumoren (LPRHHT) waarin de richtlijnen zijn besproken voor een nationale 
implementatie.
De meer dan 900 hoofd-hals patiënten die sinds 2007 zijn behandeld op de afdeling 
radiotherapie van het UMCG zullen opnieuw gesegmenteerd worden volgens de consensus 
richtlijnen, zodat vervolgens een complete set op de richtlijn aangepaste NTCP modellen 
ontwikkeld kan worden (KWF project: CITOR).
Anatomische variaties
De planning CT scan waarop een IMRT plan wordt gebaseerd is slechts een momentopname 
van de anatomie van de patiënt. Het gebruik van herhaalde beeldvorming tijdens de 
radiotherapie heeft variabiliteit van vorm, volume en positie van risico-organen laten zien 
[30, 31]. Deze variabiliteit veroorzaakt een verandering in de dosis op het orgaan [31]. 
Volledig geautomatiseerde adaptieve radiotherapie zou in theorie deze variabiliteit moeten 
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kunnen ondervangen. Klinisch relevante dosisveranderingen worden echter slechts bij 
een beperkt aantal patiënten gezien, en de adaptieve radiotherapie workflow is nog altijd 
zeer complex, arbeidsintensief en wordt onvoldoende ondersteund door commercieel 
verkrijgbare programmatuur. Het op voorhand kunnen selecteren van patiënten die baat 
zouden kunnen hebben bij adaptieve radiotherapie op basis van te verwachten dosis 
afwijkingen zou daarom zeer wenselijk zijn voor een efficiënte inzet van middelen.
In hoofdstuk 5 zijn veranderingen in de anatomie van risico-organen gedurende de 
bestraling en hun invloed op dosisparameters beschreven in een uitgebreide review. Ook 
is gekeken of er (potentiële) voorspellers van deze veranderingen zijn aan te wijzen, welke 
gebruikt zouden kunnen worden voor het selecteren van patiënten die baat hebben bij 
adaptieve radiotherapie. De parotiden zijn de meest bestudeerde organen, en slinken tot 
60-80% van hun initiële volume gedurende de radiotherapie. De meeste studies bestaan 
uit kleine patiëntengroepen en verschillen in tumor lokalisatie en in bestralingstechniek. 
Het effect van de geometrische verandering van de parotiden op de gemiddelde dosis 
in de parotiden is in 25 verschillende studies gerapporteerd en varieerde met een 
interkwartielafstand van -1.9 tot 10.4 Gy (mediaan 1.7 Gy). Om de kleine groep patiënten 
met een klinisch relevante dosisverandering te onderscheiden van de rest is gekeken 
naar mogelijke selectiecriteria. Potentiële criteria voorafgaand aan de bestraling zijn 
primaire tumorlocatie, leeftijd, BMI, parotis dosis, parotis volume en de overlap van de 
parotis met het clinical target volume (CTV). Potentiële criteria gedurende de bestraling 
zijn gewichtsverlies, diameter reductie van de nek, afname van het volume van de parotis, 
afname van de dichtheid van de parotis en afname van de afstand tussen zwaartepunt van 
de parotis en het gross tumour volume (GTV).
In hoofdstuk 6 is een model gemaakt voor het selecteren van hoofd-halskanker patiënten 
waarbij variaties in de gemiddelde dosis op de parotiden optreden van meer dan 3 Gy. 
Deze patiëntengroep zou baat kunnen hebben bij adaptieve radiotherapie aangezien een 
dosisverschil van 3 Gy overeenkomt met een verschil van 3-10% in NTCP voor het optreden 
van xerostomie (15, 16). De selectiemethode met de gemiddelde dosis op de parotis als 
input parameter was het beste in staat de patiënten te selecteren.
Vervolgstudies waarbij dosisveranderingen in doelgebieden en kritieke organen worden 
bestudeerd in grote, specifieke patiëntengroepen zullen nodig zijn om meer factoren te 
kunnen toevoegen aan de selectiemethode en de performance te verbeteren.
In dit proefschrift is de grootte en het effect van variaties in intekening en anatomie in 
kaart gebracht en zijn middelen voorgesteld voor het verkleinen van deze variaties dan 
wel het beperken van de gevolgen. De consensus intekenrichtlijnen zullen intekenvariatie 
beperken en een generieke toepassing van NTCP modellen mogelijk maken. De methode 
om patiënten waarbij een grote dosisvariatie in de parotis optreedt te selecteren kan in 
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de klinische praktijk worden gebruikt voor het selecteren van patiënten voor adaptieve 
radiotherapie, waarbij de dosis op de parotis wordt gereduceerd middels een aanpassing 
van het bestralingsplan. Op deze manier verkleint de kans op xerostomie wat zal resulteren 
in een verbeterde kwaliteit van leven.
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